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Executive summary 
Multiple sclerosis (MS) is a serious and disabling condition, which affects people in early adulthood.  It 
is the second most common cause of disability among central nervous system diseases and 
epidemiological data suggests that between 3 and 7 people per 100,000 population are newly 
diagnosed with MS each year. Neurological damage leads to problems with bodily functions, including 
impairment of muscle coordination, vision and sensation, and also results in cognitive and 
psychological dysfunction, sleep disorders, fatigue and pain. 
MS is associated with a high cost of illness, both in terms of direct and indirect costs.  Given that the 
onset of MS is in early adult life (average onset at 29 years of age) lasting over an individual’s lifetime, 
there are huge costs relating to productivity losses. There is also a significant impact on the families 
of people with MS (PWMS). Based on WHO data at global level in 2012, MS was estimated to cause 
1,165,000 disability-adjusted life years (DALYs), of which 387,000 were attributable to the European 
region and 282,000 to the Americas.  
It is becoming common practice to use magnetic resonance imaging (MRI) to diagnose and monitor 
disease activity in patients on DMTs. Current recommendations of ‘treat to target’ mean treating until 
‘no evidence of disease activity’ is reached, including no relapses, no increase in disability and no new 
or active (enhancing) lesions on their MRI scans. Meeting this objective implies regular monitoring of 
not only clinical relapse and disability progression, but also MRI activity. However, regular use of MRI 
to monitor disease activity and the effects of treatment is still not universal, though it is increasingly 
used as an outcome measure for clinical trials. A number of senior clinicians from different countries 
confirmed that MRI is routinely available in their practice, but this does not necessarily mean that it is 
common practice across clinical settings. 
There are therapies, which modify the course of the illness, known as disease modifying treatments 
(DMTs); that is, their effect is to slow disability and disease progression. However, considerable 
neurological damage (some of which may be permanent) can occur if PWMS are not given the 
appropriate treatment early enough. There is increasing focus on finding ways to identify disease 
progression as early as possible so that treatments can be adapted to prevent or delay further 
neurological damage. 
There is an urgent need to achieve better outcomes for PWMS and the evidence suggests that this 
is possible if policy makers address the following issues. 
 Diagnosis, treatment and management goals should be set to provide the best health 
outcome for every person with MS. 
 Early diagnosis and treatment are needed to secure the best outcomes for PWMS, to 
prevent or avoid irreversible health deterioration and disability progression. 
 Diagnostic imaging is an effective way of capturing disease activity early and should be 
routinely available in the management of PWMS. 
 Newer and more effective DMTs should be used both earlier and routinely while real world 
data on their long-term impact is collected. 
 Health systems should involve more actively PWMS in decisions about their disease 
management. 
 MS specialists should be involved in drawing up a treatment plan for each PWMS. 
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 (Further) robust evidence should be generated and used in order to make appropriate decisions 
about care management in MS strategies. 
 Robust epidemiological, clinical and disease management data are needed internationally 
to inform better decisions for priority setting in MS. 
 National registries should be in place and the data from them should be routinely used; 
the production of such evidence should be adequately resourced.   
 Data should be updated on an ongoing basis and should incorporate dimensions for which 
little validated information currently exists; for example, registry data should be amended 
to allow for collection and use of standardised information on MRI use across country 
settings. 
 Updated and internationally comparable evidence on the use of diagnostic imaging as a 
means of capturing disease activity should be generated as a priority. 
 Health gain and quality of life data should take account of dimensions that patients say 
have a significant impact on their daily lives; many of these items are not captured by 
generic tools often used by HTA agencies internationally (e.g. EuroQol 5 dimensions 5 
levels (EQ-5D-5L) questionnaire). 
 Greater consistency is needed in collecting economic data and evaluating the economic 
impact of MS to ensure that comparisons across settings can be made. 
 
 Improve the responsiveness of health care systems to new evidence on MS. 
 Healthcare systems need to be able to respond dynamically as new evidence emerges on 
the diagnosis, treatment and psychosocial support of MS patients as well as the long-term 
economic evidence on the impact of MS. 
 Updated guidance on MS management should be developed as new evidence becomes 
available on the use of imaging and disease modifying therapies and should be 
implemented promptly. 
 Incentives should support improvement in clinical practice and the incorporation of new 
evidence on MS management in health care decision-making, especially if such evidence 
is linked to improvements in quality of care and health outcomes. 
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1. Multiple sclerosis: Epidemiology, Diagnosis and 
Clinical Pathways 
1.1.  Epidemiology  
Multiple sclerosis (MS) is an inflammatory 
disorder of the central nervous system (CNS). 
In Europe and the US, MS is the leading cause 
of non-traumatic neurological disability in 
young adults1,2. The distinctive aspects of MS 
are its manifestation in early adulthood 
(average age of onset of first symptoms of the 
disease is 29 years) and its chronic nature. 
Inflammation can occur in any area of the 
brain, spinal cord and optic nerve with 
commonly occurring symptoms including 
depression and anxiety, limitations in mobility, 
reduced hand and fine finger control, unclear 
speech, urinary and faecal incontinence and 
cognitive impairment, causing memory and 
concentration difficulties, problems with 
words, and compromising visuospatial 
abilities, planning and problem-solving. 
Depending on the location of inflammation 
within the CNS, MS can present with a range of 
symptoms, with variability in severity and 
disease course.  
There are three main types of MS. The most 
common, affecting about 85% of people with 
MS, is relapsing-remitting MS (RRMS), where 
patients experience temporary disability due 
to acute neurologic symptoms known as 
relapses, followed by remission periods where 
symptoms abate and disability may 
disappear3,4. RRMS is usually followed by 
secondary progressive MS (SPMS), where 
relapsing-remitting patterns are no longer 
evident due to a steady increase in disability.  
Box 1 
Issues in determining MS Epidemiology 
Although there is considerable literature 
covering prevalence studies, the lack of 
harmonised data collection across countries 
may limit the reliability of the available data. 
Moreover, the absence until 2010 of universal 
diagnostic criteria (see section 1.2 on 
diagnosis) means that data from past 
epidemiological studies may not accurately 
reflect the true MS population because of 
variable classification of people with MS across 
studies (i.e. individuals with definite, possible 
and/or probable MS)5. In addition, the limited 
availability of country-specific MS registries 
worldwide6,7 has resulted in methodological 
inconsistencies in recruitment. Where 
nationwide surveys or registries have been 
employed, prevalence rates have been 
consistently higher compared to studies where 
recruitment methods relied on physicians’, 
clinics’, or hospitals’ records8. There is 
significant fluctuation of figures reported 
within countries and the epidemiological 
picture for each country can only be based on 
approximations. The methodological issues 
that affect prevalence data apply also to 
incidence data. In addition, difficulties in 
capturing the true onset of MS further may 
also impede accuracy of incidence 
measurements, resulting in significant scarcity 
of MS incidence studies5. 
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Table 1: Types of MS 
 MAIN TYPES OF MS 
Relapsing–Remitting MS 
(RRMS)                        
- 85% of MS population 
- Self-limited attacks (24hrs) with periods of remission (1 month)9,10  
- Acute attacks over days/weeks  
- Usually accompanied by periods of partial or complete recovery over 
several weeks 
Secondary Progressive MS 
(SPMS)  
 
- 50% of RRMS cases 
- Progressive disease, independent of relapses10  
- Ultimately attack rate is reduced with remissions, and plateaus11  
- Steady deterioration in function 
Primary Progressive MS 
(PPMS)  
 
- 10%-15% of MS population  
- >1year disease progression with occasional plateaus and temporary 
improvements12  
Steady decline in function from the beginning without acute 
attacks13  
 SUBTYPES OF MS 
Rapidly Evolving Severe (RES) 
RRMS (subtype of RRMS) 
- 2 disabling relapses in 1 year 
- 2 consecutive magnetic resonance imaging (MRI) scans with 
increasing lesions 
Progressive–Relapsing MS 
(PRMS) (subtype of SPMS) 
- 5% from onset (least common type) 
- Progressive disease with acute relapses (with or without recovery) 
- Continuous progression between relapses11 
 
 
Primary progressive MS (PPMS) is described by a more steady increase in disability with the absence 
of acute relapses.  Other less common forms of MS include rapidly evolving relapsing remitting MS 
(RES) and progressive relapsing MS (PRMS) (Table 1). MS is estimated to affect nearly 2.5 million 
people (30 per 100,000) at a global level and is believed to be more prevalent in areas further from 
the equator8 (Figure 1). MS consistently presents with higher prevalence rates (per 100,000) in Canada 
(291), North America (140), UK (203.4) and Germany (128)8,14,15 and lower prevalence rates in Sub-
Saharan Africa (2.1), East Asia (2.2), and South East European countries such as Romania (20-30) and 
Bulgaria (50)16,17. France has the lowest rates among other north European countries (94.7)16.  
Incidence estimates mimic prevalence figures, with a global mean annual rate of 2.5 per 100,00018 and 
4.3 per 100,000 in Europe17 (see also Appendix Figure 1).  Methodological issues limit the reliability of 
prevalence and incidence data (Box 1) and more robust methods leading to more reliable 
epidemiological data on MS are urgently needed to allow for a complete understanding of its 
prevalence and incidence, to enable comprehensive and meaningful comparisons across 
populations.17 
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Figure 1: World prevalence (per 100,000) of MS per country (2013)  
 
Source: MSIF, 201319. 
 
1.2. Diagnosis 
It is difficult to identify exactly when MS begins due to the many different symptoms and the variation 
in early signs and symptoms between individuals. It is not uncommon for a diagnosis to take several 
months or longer as other possible causes of the symptoms need to be excluded because most people 
who experience unexplained symptoms do not have MS.  
There are a range of tests that neurologists use to confirm whether a person has MS, including 
magnetic resonance imaging (MRI), evoked potentials and lumbar puncture20. MRI is able to confirm 
a diagnosis in over 90% of people with MS, but it is important to correlate the MRI results with the 
clinical manifestations. This is captured by the McDonald criteria, which include clinical, laboratory, 
and MRI tests 21. According to these criteria, individuals with a single attack of neurological symptoms 
are considered to have clinically isolated syndrome (CIS). For a diagnosis of clinically definite MS 
(CDMS) to be made, there must be a second clinical attack, or evidence of dissemination of MRI lesions 
in time and space. 
Use of the McDonald criteria has enabled earlier diagnosis with the possibility to start treatment 
earlier. They allow a diagnosis of RRMS at the time of a single clinical attack when there is MRI 
evidence of both new (gadolinium-enhancing T1 lesions) and old (non-gadolinium-enhancing T2 
lesions) lesions simultaneously appearing21.  
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1.3. Clinical pathways and pharmaceutical care  
People do not die directly from MS, 
but evidence shows that on 
average life expectancy of people 
with MS is shorter than that of the 
general population (76 years 
compared to 83 years for those 
without MS).22 Although it is 
unclear whether disease-
modifying treatments (DMTs) 
influence life expectancy, their 
impact on the early stages of the 
disease (inflammatory component) 
does reduce the relapse rate. 
Despite a profound influence on 
the immune system, a clear effect 
of these medicines on later stages 
of disease (preventing or delaying 
disability) is yet to be confirmed. 
The degenerative process consists 
of irreversible brain damage and 
loss and results in disability 
progression without relapses.  
The main therapeutic goals of 
DMTs are to act earlier, on the 
inflammatory component of the 
disease, and to reduce clinical 
relapses with the goal of 
decreasing disability and MRI 
lesions13,23.  Current discussion 
among MS experts24 suggests that 
the target of treatment should be 
those falling under ‘no evidence of 
disease activity’ (NEDA). 
The most widely used definition of 
disease activity for NEDA is based 
on three separate factors: (a) 
active MRI lesions, (b) relapses and 
(c) disability progression (NEDA-
3)25. 
 
 
Box 2 
Clinical Pathways and Pharmaceutical Care –  
Disease-modifying treatments (DMTs) 
Natalizumab (Tysabri, Biogen), an injectable monoclonal 
antibody introduced in 2004, is an effective medicine but 
comes with a potentially fatal infection known as progressive 
multifocal leukoencephalopathy (PML) that occurs in 
approximately 1 in every 500 people treated26. Natalizumab is 
not the only DMT to have PML as a side effect.  Alemtuzumab 
(Lemtrada, Genzyme) is another injectable monoclonal 
antibody introduced in the market more recently. However, a 
few cases of PML have been reported with both fingolimod 
and gimethyl fumarate. 
Three oral DMTs have been approved since 2010 for 
individuals with RRMS: = fingolimod (Gilenya, Novartis), 
teriflunomide (Aubagio, Genzyme) and dimethyl fumarate 
(Tecfidera, Biogen Idec). Based on the results from Phase III 
trials, these new oral therapies appear to be at least as 
effective (teriflunomide) or more effective (fingolimod, 
dimethyl fumarate) than  interferon (IFN) and glatiramer 
acetate (GA) 27,28.  
Tolerability is excellent, and the oral route of administration is 
preferred over injection by many individuals. Safety issues in 
the 2-year trials have been rare, and open-label Phase IV 
observation studies to date have not identified new long-term 
safety problems6,29. Less frequently used medicines include 
mitoxantrone, rituximab, methotrexate, azathioprine and 
cyclophosphamide.  
The efficacy of DMTs in reducing the rate of relapses in 
patients with relapsing-remitting MS (RRMS) and for slowing 
the course of MS progression has been shown in several 
studies. Efficacy is higher when treatment is initiated early30-33 
and early use of a DMT may reduce permanent neurological 
damage, improving patient prognosis. 
Studies indicate that early treatment with DMTs can delay the 
development of CDMS in patients with CIS28,34-38. Brain 
atrophy, which accompanies axonal damage and loss, can be 
observed early in the MS disease course, even in patients with 
CIS30,39,40 but early treatment with IFN beta-1a has been shown 
to reduce the rate of atrophy in these patients40. Conversely, 
delays in diagnosis and treatment, even after patients have 
developed CDMS allows brain damage to accumulate and 
brain atrophy to progress, leading to the development of 
severe and irreversible neurological disability30,41. In addition 
to the disability, the delay may result in poorer response to 
DMTs with an overall negative impact on MS prognosis3,8,42-47. 
For these reasons, early DMT use in MS patients has been 
recommended in a number of guidelines9,48,49.
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Brain volume loss (BVL) has been 
recently proposed as an additional 
fourth component to be used to 
detect disease activity (NEDA-4), 
while a fifth is ‘no marker of 
neuronal inflammation in the 
cerebrospinal fluid or blood’ (NEDA-
5). It is anticipated that the 
definition of NEDA will evolve with 
technological innovation and 
clinical practice. A future definition 
will likely need to include patient 
relevant outcome measures 
(PROMS), focal grey matter disease 
activity, a whole and/or a regional 
brain atrophy metric and possibly 
fluid biomarkers50,51.  
Interferon (IFN) and Glatiramer 
Acetate (GA) are injectable 
therapies launched in the mid-
1990s; they are often referred to as 
‘platform therapies’ since they 
provide baseline 
immunomodulatory action and can 
be administered for an extended 
period of time. Studies have shown 
that platform therapies reduce the 
relapse rate of approximately 30% 
and the MRI markers of disease 
activity8,40,42. These injectable 
therapies have been used for over 
15 years and have manageable side-
effect profiles with minimal serious 
side effects. In the years since their 
approval, long-term safety of these therapies has been extraordinary strong, with limited side effects 
(flu-like side effects for IFN and injection site reactions for GA) and few identified serious long-term 
risks of continued therapy3,44. The common side-effects and dislike of injections contribute to injection 
fatigue, non-adherence45, and long-term non-persistence with both IFN and GA.  
Newer MS therapies (natalizumab, fingolimod, teriflunomide, dimethyl fumarate, alemtuzumab) have 
improved efficacy, offer very good safety and have greater tolerability, and more acceptable routes of 
administration. A list of DMTs currently available and their recommendations are presented in box 2 
and appendix tables 1-2.  
Box 3 
Clinical guidelines 
Different clinical guidelines published across international 
settings provide advice regarding the care of adults with MS 
(Appendix Table 3). The following key aspects were identified as 
important in the management of MS: 
MRI in clinical practice. There is agreement that new MRI 
lesions are a more sensitive indicator of inflammatory disease 
activity than clinical relapses. Many clinicians now substitute 
MRI activity for clinical activity in the classification, diagnosis 
and management of MS. Annual review conducted by the MS 
specialist neurologist, with MRI activity routinely assessed over 
12-month intervals (at the direction of the neurologist) 
combined with clinical relapse activity will allow treatment 
decisions to be tailored to the individual’s situation. 
Early treatment. Clinicians should consider starting treatment 
for individuals within 12 months after a first symptom if MRI 
establishes evidence of MS diagnosis (2010 McDonald criteria) 
or predicts a high likelihood of recurrent episodes (i.e. 
development of MS), and perhaps if cerebrospinal fluid 
examination shows markers of inflammation. 
Early treatment with DMTs. Immunotherapies appear 
particularly helpful when given early to people with active 
relapsing–remitting disease, before there is fixed disability or 
secondary progression. Although it seems plausible that 
reducing relapse rate and MRI lesion accumulation would 
favourably influence the long-term prognosis, there are as yet 
no peer-reviewed controlled trial results showing long-term 
benefit.  This may be due to lack of sufficient follow up time, but 
as there is no consensus on the matter more research is needed. 
Treatment target.  It is not yet clear whether treatment should 
aim for a target such as ‘no evidence of disease activity’— either 
clinical or radiological. There is no long-term evidence on which 
to offer guidance. Therefore, whether a single relapse should 
trigger an immediate treatment escalation is not known 
although a number of MS specialists adopt this approach.  
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The economic benefits of DMTs have been extensively discussed in the literature9,46-49. The main 
limitation reported is the lack of long-term evidence on the effect of DMTs: nearly all studies made 
use of old natural history data, and comparative efficacy data from head-to-head clinical trials or meta-
analyses were not commonly used. Switching to other DMTs following initial treatment 
discontinuation was not commonly considered and information regarding how well a model was 
validated was rarely reported. Harmonised wide scale collection of both clinical and economic 
evidence with the support of national registries would allow more comprehensive analyses and 
comparisons across populations. 
Although the economic impact of early use of DMTs has been addressed in a limited number of studies 
only, these have indicated that initiation of a DMT in the early stages of disease (after diagnosis of 
RRMS or even at the stage of CIS) may be cost-effective in the long term52. The outcome of reduced 
relapses, hospitalisation and indirect costs and QALYs gained seemed to outweigh the long term costs 
of DMTs, although more research is needed to gather evidence of long term benefit.  
Different clinical guidelines published across international settings provide advice regarding the care 
of adults with MS (box 3). 
 
2. Aims and objectives of this report 
This report addresses the significant impact of MS on the health and wellbeing of both people with 
the disease, and their caregivers, along with its broader socio-economic impact.  Specifically, the 
report aims to: 
 Present the evidence for and generate debate on the merits of a likely paradigm shift in the 
management of MS, including the use of better (and more accurate) diagnostic follow up to 
monitor disease progression and the earlier use of DMTs to achieve better outcomes for 
individuals; 
 Assess the socio-economic and personal impact of such a paradigm shift compared to the 
current status. 
In fulfilling these aims, the report objectives are to: 
 Provide fresh estimates of the socioeconomic burden and health related quality of life 
(HRQoL) of people affected by MS; 
 Explore the impact that a paradigm shift in the management of MS could have on health 
outcomes and resource utilisation; 
 Identify whether the views of PWMS and treating physicians are aligned on MS management 
and to explore the factors which influence these views; 
 Identify the criteria driving value assessments of MS pharmaceutical treatments by analysing 
health technology assessment (HTA) recommendations and their impact across different 
settings. 
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3. Methods 
Primary and secondary data sources were used in the study to produce quantitative and qualitative 
evidence. Primary data sources included the collection of resource use and health-related quality of 
life data from PWMS and their caregivers together with insights about treatment pathways from 
clinicians. A series of surveys were designed to capture a better understanding of the multiple domains 
of MS burden on PWMS and their caregivers, and the experience and views of PWMS, caregivers and 
clinicians about early diagnosis and the drivers for changing to new (including oral) disease modifying 
treatments. The surveys contributed to the following objectives: to estimate the socioeconomic 
burden and HRQoL of PWMS; to explore the impact that a paradigm shift in the management of MS 
could have on health outcomes and resource utilisation; and to identify whether the views of PWMS 
and treating physicians are aligned on MS management and to explore the factors which influence 
these views. Secondary data sources included an analysis of health technology assessment (HTA) 
recommendations and their rationale, across different settings that use this particular tool, with a 
view to understanding the type of decision-making and the levers and criteria that individual HTA 
agencies use to enable the coverage of new technologies. 
 
3.1 Primary data collection from PWMS and their caregivers  
An observational study of adults with MS (at all levels of self-reported disease severity) and their 
caregivers was administered through anonymous online surveys available in English, French, German, 
Greek, Italian, Swedish and Romanian. Recruitment was facilitated by national and international MS 
organisations and MS-centres; 8 of 11 organisations/centres approached (about 73%) supported the 
dissemination of the online survey in English and/or local languages.  The countries approached 
included: the UK, Sweden, France, Germany, Italy, Greece, Romania, and the USA and covered: 
different access to MS treatments and services in terms of diagnostic criteria and clinical management 
of MS (availability of neurologists, MS treatment guidelines and clinical practice); a range of 
reimbursement policies including eligibility for treatment (restrictive HTA decisions and market access 
delays); affordability of MS treatments; and availability of registries or databases7 .  The dissemination 
strategy included blog, website, email, and social media across: USA (two organisations), UK (two), 
Germany (one), France (one), Romania (one), and pan-European (one).   
The surveys captured data on: direct medical costsa (medication costs, visits, hospitalisation); direct 
non-medical costs (help from caregivers); indirect costs (productivity loss); PWMS and their caregiver 
HRQoL (EQ-5D-5L)53; aspects of the health status that are valued by PWMS; their disability (Barthel-
Index)54 b; their satisfaction with the treatment received; burden among caregivers55 c; participants’ 
experience of first MS symptoms; diagnosis and treatment with DMTs (orals and injectables); 
demographic variables, and disease information.  
                                                          
a Types of MS related costs are explained in figure 2. 
b The Barthel Index (BI) consists of 10 items that measure a person’s daily functioning, particularly the activities of daily living 
and mobility. Response options range from 0 (severely dependent) to 20 (independent). 
c The Zarit Burden Interview, a popular caregiver self-report measure used by many aging agencies, originated as a 29-item 
questionnaire (Zarit, Reever & Bach-Peterson, 1980). The revised version contains 22 items. Each item on the interview is a 
statement which the caregiver is asked to endorse using a 5-point scale. Response options range from 0 (Never) to 4 (Nearly 
Always). 
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The societal, HRQoL and economic impact of MS management were evaluated for: the overall sample; 
comparing different country settings and types of MS; and comparing experience of MS management 
by early diagnosis [<12 months after first symptom] vs. late [>12 months after first symptom]. The 12 
month cut off adopted here followed current guidance from the Association of British Neurologists56 
that initiation of DMT within 12 months of a single neurological attack with MRI enhancing lesions 
should be considered. 
 
3.2 Primary data collection from clinicians 
A separate online survey (supplemented by face-to-face/telephone discussions) was designed to 
collect information from clinicians about their experience of MS treatment. The target group was MS 
expert physicians across the US and Europe who were approached via personal contacts and patient 
organisations. A series of MS specialists participating in the first conference of the European 
Association of Neurologist 2015 were also invited to participate.  
The survey comprised four sections:  
 Issues relating to symptoms and diagnosis (the source of information on MS diagnosis, 
treatment and management; the tools they use more frequently for diagnosis of MS; the age 
most of their patients experience the first MS symptoms/ receive a diagnosis of MS; the delay 
between first symptoms and diagnosis of MS in their experience);  
 The use of DMTs (how long following the diagnosis of MS they usually start to actively treat a 
PWMS; which DMTs they use as a 1st or 2nd line treatment; the percentage of their patients 
for whom they prescribed it; when they escalate from 2nd to 3rd line treatments and the DMT 
they prescribe; the attributes that are more important when selecting a DMT; whether their 
patients contribute to the decision making process);  
 A series of case studies picturing early treatment as well as switching treatment scenarios; 
 Information about themselves (training/practice experience). 
 
3.3 Analysis of secondary data: Impact of HTAs  
The review of HTA decisions provided an in-depth understanding of similarities and differences in HTA 
assessments across different countries. Analysing HTA recommendations and their impact allowed the 
criteria driving value assessments in MS pharmaceutical treatments to be identified.  
A number of country-specific case studies were conducted on 8 different MS treatments (IFNβ 1a IM 
(Avonex), alemtuzumab (Lemtrada), IFNβ 1a SC (Rebif), glatiramer acetate (Copaxone), teriflunomide 
(Aubagio), dimethyl fumarate (Tecfidera), fingolimod (Gilenya), natalizumab (Tysabri)).  The countries 
selected (England, Scotland, Sweden, France, Germany and Canada) have notably different 
approaches to assessing the value of a medicine and the study sought to clarify differences in the 
evaluation of the evidence and which factors may drive different access to MS treatments across 
countries. The pharmaceutical products considered in the analysis were all indicated for RRMS, and 
underwent HTAs prior to June 2015 in at least three of the study countries. For each HTA assessment 
a series of information points on the decision-making process were identified and analysed as follows:  
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 Clinical evidence evaluated (type of trials, comparators considered, primary, secondary and 
HRQoL outcomes); 
 Safety profile and adverse events; 
 Economic evidence (type of cost-effectiveness analysis and comparator considered); 
 Clinical and economic uncertainties (concerns raised around the clinical and economic 
evidence presented by the manufacturer, see Appendix Tables 5-6); 
 Stakeholder input (input from PWMS or clinical experts that influenced the outcome);  
 Other factors (specific disease and treatment characteristics that influenced the outcome); 
 Time lapse between marketing authorisation and completion of the HTA assessment as 
indicator of timely access to treatment, see Appendix Table 7. 
For each dimension, HTA data were compared across case studies and medicines of interest. The 
collection and analysis of HTA data were based on a standardised analytical framework developed at 
LSE57. 
 
4. Evidence on the socio-economic impact of MS  
4.1 MS treatment and monitoring 
In MS the central nervous system (CNS) is affected and the neurological damage seems to occur mostly 
in the early phase of the disease. There is evidence indicating that disability accumulation and health 
status deterioration are related to the inflammatory attacks to the CNS in the early stages of the 
disease suggesting an early therapeutic window of opportunity when greatest benefit can be obtained 
from using the most effective intervention as early as possible39. Consequently, early diagnosis and 
treatment are needed to secure the best outcomes for PWMS, to prevent or avoid irreversible health 
deterioration and disability progression. 
DMTs are able to reduce the inflammation of nerve cells caused by MS and to alter the course of the 
disease by slowing disability and disease progression.  This is in line with the treatment goals of 
PWMS58. All the licensed DMTs for MS reduce relapse rate and MRI lesion accumulation in RRMS with 
varying levels of efficacy and there is no agreed gold standard treatment. DMTs appear to be most 
helpful when given early to people with active RRMS, before there is fixed disability or secondary 
progression.  The evidence suggests that newer and more effective disease modifying treatments 
should be used both earlier and routinely while real world data on their long-term impact is collected. 
Despite current treatment paradigms targeting relapse as a proxy for disease progression, it is now 
evident that MS should be monitored on a more regular basis by alternative diagnostic means, and 
different measures of disease progression adopted in order to judge whether a change in treatment 
is indicated25,51,57,59,60. This would allow access to more novel therapies earlier in the disease. Evidence 
from the literature supports the use of new MRI lesions as a more sensitive index of inflammatory 
disease activity, as opposed to clinical relapses only. MRI is now increasingly used to monitor disease 
activity in PWMS on DMTs and neuroscience centres with expertise in MS increasingly need ready 
access to MRI and other diagnostic services in order to monitor PWMS on DMTs. Diagnostic imaging 
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is an effective way of capturing disease activity early and should be routinely available in the 
management of MS. However, lack of neurologists specialising in MS is one of the main barriers to 
access in some countries. 
When considering potential DMT options, PWMS and neurologists should discuss together the 
benefits and potential risks of medicines, as well as monitoring requirements. Other factors that are 
personally important to a PWMS, such as work and family, should be factored into decisions and 
individual treatment plans can be agreed based on the type of MS and personal circumstances. PWMS 
should be given accurate information about what to expect from treatment. In recent years guidelines 
have been developed at national and/or international level to support the application of current 
knowledge of best practice in clinical management.  Prescribing guidelines should be aligned with the 
latest accepted diagnostic criteria and treatment options to give PWMS the opportunity to receive the 
best available treatment and support promptly, once diagnosis is confirmed. Updated guidance on MS 
management should be developed as new evidence becomes available and the guidelines should be 
implemented promptly. 
 
4.2 Costs and Quality of Life 
MS is a ‘hidden disease’ and the extent of its impact is not always visible to others. A number of 
symptoms limit the ability of PWMS to work; these include depression and anxiety, limitations in 
mobility, reduced dexterity, slurred speech, urinary and faecal frequency and urgency, and cognitive 
impairment causing memory and concentration difficulties. The disease is associated with a variety of 
direct and indirect costs and due to its nature there are also intangible costs, which may include 
additional dimensions of burden related to pain and impact on quality of life for PWMS and their 
family/caregivers (Figure 2).  
MS is estimated to cause 1,165,000 disability-adjusted life years (DALYs) globally, of which 387,000 
are attributable to Europe, and 282,000 in the Americas61. Disease progression leads to disability, 
which affects individuals’ and their informal caregivers’ social functioning, quality of life and reduced 
productivity, resulting in increased burden on health systems and society and significant productivity 
losses. The proportion of total costs attributable to medical costs (e.g. medical costs, inpatient care), 
non-medical costs (e.g. formal and informal care by family or friends) and other cost categories 
(indirect costs related to productivity losses) varies across studies.62 Despite applying different 
methodologies and reporting on different types of costs, all economic studies in MS clearly highlight 
the high societal cost of this disease. They also clearly illustrate how different health-care systems 
provide different levels of services for PWMS.  
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Figure 2: Economic impact of MS: Conceptual model and cost categories  
 
 
4.2.1. Costs  
The proportion of total costs attributable to direct medical costs (e.g. prescriptions, hospitalisations), 
direct non-medical costs (e.g. formal and informal care by family or friends) and other cost categories 
(e.g. indirect costs related, among others, to productivity losses; or intangible costs related to the 
impact on quality of life, pain or suffering) vary across settings8,62-65.  
Available evidence suggests that the average PWMS is 47 years old, with an average annual cost of 
US$41,133 (€54,844d). Direct costs accounted for approximately 70% of total costs, of which the main 
component was medication costs. Only 40% of PWMS are active in the labour market65. Additional 
evidence found that in the USA, the total healthcare costs range between US$8,528 to US$54,244 
(€11,371 to €72,325e) per person per year, with direct costs accounting, on average, for 77% and 
indirect costs for the remaining 23% of the total64. Total costs increase with progressive disease. 
Intangible costs were estimated at around €13,000 per person (in 2005)63. Evidence from Europe 
highlighted that the total mean annual costs per PWMS were €18,000 for mild disease (Expanded 
Disability Status Scalef (EDSS) <4.0g), €36,500 for moderate disease (EDSS 4.0–6.5h) and €62,000 for 
severe disease (EDSS >7.0i)63 . Appendix Table 4 provides a summary of cost of illness studies. 
Pharmaceutical costs generally decreased from moderate to severe MS due to the lack of MS-specific 
treatments for severe disease. Indirect costs tended to be more of a contributing factor as individual 
                                                          
d At 2013 exchange rates. 
e At 2013 exchange rates. 
f Expanded Disability Status Scale (EDSS) score is a measure of disease activity weighted towards the physical, especially 
mobility, aspects of the disease and is used to monitor changes in the level of disability over time (from 0= no disability to 
10=death) 
g EDSS of 4 = Able to walk without aid 500 meters. 
h EDSS of 6.5 = Constant bilateral support (cane, crutch or braces) required to walk 20 meters without resting. 
i EDSS of 7 = Unable to walk beyond 5 meters even with aid, essentially restricted to wheelchair, wheels self, transfers alone; 
active in wheelchair about 12 hours a day. 
Tangible costs, direct costs
1 Medical costs 
(doctor visits, tests, prescriptions, assistive 
devices, therapy, long-term care)
2 Non-medical costs 
(home/auto modifications, transport,
formal care, informal care)
Tangible costs, indirect costs
1 Increased morbidity 
(work loss, work change)
2 Early mortality 
(loss of earnings )
3 Impact on family and friends
(employment/health)
Intangible costs
1 Pain, suffering
2 Quality of life impacts
3 Stress
4 Quality of life impacts on family and 
friends
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disability increased e.g. higher Expanded Disability Status Scale (EDSS) scores. The highest cost is seen 
among individuals with an EDSS score of 8j –9k.  
The use of health care resources and services is not only influenced by severity and disease activity 
(relapses), but also by the organization and availability of care and the ease of access. The amount of 
informal care is generally a function of the extent of services offered by individual healthcare systems. 
Limited healthcare services available to PWMS usually lead to a greater use of informal care. Although 
a significant proportion of total costs relate to informal caring arrangements, this cost element is most 
often not reimbursed by health care systems, impacting both family income and caregiver quality of 
life.  
 
4.2.2. Impact on quality of Life of PWMS and their caregivers 
There is a clear deterioration in health outcomes of PWMS compared with the healthy population, 
and the deterioration may increase with the severity of the disease. A decrease in individual’s 
preferences for specific health outcomes (utility loss) in PWMS compared with the general population 
varied between the case studies of interest62,63. European evidence showed that quality of life scores 
among PWMS were similar across countries at around 0.70 (70% of perfect health) for a person with 
an EDSS of 2.0 (with minimal disability in one functional system) and around 0.45 (45% of perfect 
health) for a person with an EDSS of 6.5 (with constant bilateral support with cane, crutch or braces 
required to walk 20 metres without resting). People with SPMS reported a higher symptom burden 
than individuals with RRMS, highlighting the need to prevent progression from RRMS to SPMS66.  
The stress and physical burden of caring for a person with MS may have an adverse effect on the 
psychological and physical health of caregivers and increase their health care use8.  The burden on 
caregivers is substantial, and its amount varies by the PWMS’ level of disability. Caregivers experience 
a high socioeconomic burden as a result of their role, with caregivers for individuals with SPMS 
experiencing a more significant burden than those of individuals with RRMS, reflected in their 
decreased ability to be employed full-time and the effect of their role as a caregiver on their work67.   
EuroQol 5 dimensions 5 levels (EQ-5D-5L)l is one of the most widely used utility measures in MS and 
it is currently used to evaluate the cost-effectiveness of different interventions. However, the 
challenge of using such a measure in people with a specific health condition, such as MS, is that it may 
not capture all of the domains that are impacted upon by the health condition. If important domains 
are missing from the generic measures, the value derived will be higher than the real impact creating 
invalid comparisons across interventions and country settings. Several disease-specific HRQoL 
instruments have been validated for use in MS patients. These include: the PRIMUS (Patient Reported 
Outcome Indices for Multiple Sclerosis)l, a set of outcome measures including assessments of HRQoL 
and activity limitations; the MSQLI (Multiple Sclerosis Quality of Life Inventory), a series of instruments 
                                                          
j EDSS of 8 = Essentially restricted to bed, chair, or wheelchair, but may be out of bed much of day; retains self-care functions, 
generally effective use of arms. 
k EDSS of 9 = Helpless bed patient, can communicate and eat. 
l EuroQol 5 Dimension 5 level (EQ-5D-5L) is a standardised instrument for use as a measure of health outcome. It consists of 
five dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) each of which can take one of 
five responses. The responses record five levels of severity (no problems/slight problems/moderate problems/severe 
problems/extreme problems) within a particular EQ-5D-5L dimension. Utility values vary between 0 (dead)—1 (full health). 
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consisting of 10 individual scales providing a quality of life measure that is both generic and MS-
specific; or the 12-item Multiple Sclerosis Walking Scale (MSWS-12). In clinical practice, MS-specific 
questionnaires appeared to be more appropriate than generic instruments due to a better ability to 
capture HRQoL differences in MS patients. In economic evaluations more methodological work is still 
needed to support the use of utility scores derived from disease specific instruments into decision 
modelling68.   
 
4.2.3. Access to Disease Modifying Treatments 
Although DMTs can reduce relapse rates and evidence of disease activity can be identified using 
magnetic resonance imaging (MRI)69, access to treatments and services can vary significantly across 
countries. WHO19 found that only half of the treatment-eligible population among all countries 
worldwide that contributed to the Atlas of MS 2013, actually did receive a DMT; with patient choice 
(61.1%), reimbursement policy (57.7%), clinical practice (29.6%) and access to MS healthcare 
professionals (27.8%) being the main reasons for not receiving a DMT despite being eligible.  When 
used, DMT high prices may increase the impact of direct costs on the total MS related annual costs, 
although treatment costs are likely to be offset in the long-term by increased productivity at work.  
 
5. An analysis of patient, caregiver and clinician primary 
data on costs, HRQOL and clinical practices  
5.1. Primary data analysis: People with MS  
In conducting primary research across settings, the objectives were to estimate and compare the 
costs, HRQoL, and impact on daily living reported by PWMS and their caregivers across international 
settings. This would allow to: (i) address the lack of data on the multiple domains of MS burden on 
affected people as well as their HRQoL and experience of care; (ii) explore the potential impact that a 
paradigm shift in the management of MS could have on health outcomes and resource utilisation; (iii) 
compare the views of PWMS with the views of clinicians on early diagnosis and preferences related to 
a possible move towards early diagnosis and treatment with new (including oral) disease modifying 
treatments. 
 
5.1.1. PWMS: responses and sociodemographic data   
Valid responses suitable for analysis were received from 246 individuals. The majority of responses 
came from France (n=97, 39%) followed by USA (n=70, 28%), Romania (n=44, 18%), UK (n=25, 10%) 
and Germany (n=10, 4%). The majority of individuals were females (203, 83%), with an average age of 
43.7 years. The reported mean age at first symptoms and diagnosis were 30.4 and 35.2 respectively. 
The majority of the individuals were diagnosed with RRMS (175, 66%), followed by SPMS (30,11.32%) 
and PPMS (26, 9.8%). For 34 individuals (12.8%) the type of MS was unknown. About half of the 
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individuals reported an early MS diagnosism (118 or 48%). Further detail is provided in Appendix table 
8. 
5.1.2 PWMS: their treatment for MS  
About 82% (203/246) of PWMS started on DMTs and slightly more than half were currently receiving 
DMTs (135, 54.9%) at the time of completing the survey; of those taking DMTs, 58 (58/135; 42.9%) 
were treated with oral DMTs. Further detail on the use of DMTs according to type of MS is reported 
in Table 2. Evidence from the PWMS survey confirmed the choice of first and second line treatments 
reported in the literature (appendix tables 1 and 2).  More details are available upon request.  
 
Table 2: Use of Disease Modifying Treatments (DMTs) according to type of MS  
ALL SAMPLE (N=246,            
100%) 
Started on DMT 
(N=203, 100%) 
  Changed between first 
and current DMT (N=75, 100%) 
Currently   on DMT 
(N=135, 100%) 
RRMS (n=164, 67%) 148 (72.9%) 48 (64%) 106 (78.5%) 
SPMS (n=28, 11%) 24 (11.8%) 12(16%) 8 (5.9%) 
PPMS (n=21, 9%) 9 (4.4%) 4 (5.3%) 4 (2.9%) 
Unknown (n=33, 13%) 24 (11.8%) 11 (14.6%) 17(12.6%) 
Primary progressive multiple sclerosis (PPMS); Secondary progressive multiple sclerosis (SPMS); Relapsing 
remitting multiple sclerosis (RRMS). 
 
5.1.3 PWMS: Views on MS management  
When treatment should be started. Respondents had varied views.  67.5% reported that treatment 
should be started at clinical diagnosis whereas 31.3 % thought it should be at first symptoms. The 
former group was aware of the potential side effects of treatments and preferred to delay possible 
risks as much as possible. The latter group was knowledgeable about the irreversible effect of MS on 
brain volume and the associated disabilities.   
The preferred sources of information for MS management are listed in Figure 3. This is a young 
population that may be expected to use online resources, whereas only a few of them reported online 
support groups, social media or online forums as preferred source of information (less than 30% for 
each type of source). Only 31 respondents (12.8%) discussed with family and friends their experience 
of MS and 27 (11.1%) respondents attended support or self-help group meetings.  
When making decisions about their treatment: 50% preferred to make final decision (I prefer to make 
the final decision alone, 21%; I prefer to make the final decision after seriously considering my doctor's 
opinion, 29%); 27% preferred to share responsibility with the doctor; and 23% of respondents 
preferred the doctors to decide on their behalf. 
 
                                                          
m Early MS diagnosis/treatment was defined as diagnosis/treatment made within the first 12 months from the first 
symptom of MS. 
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5.1.4 PWMS: Tangible/intangible costs and satisfaction with the healthcare service received 
Tangible costs - direct medical costs, informal care costs and loss of productivity at work.  Total 
average annual costs were €40,313 (SDn= €18,352). The majority of costs were associated with direct 
medical costs €21,093 (medicines, consultations with a specialist, hospitalisations), followed by 
indirect costs €17,110 (productivity loss) and direct non-medical costs (€2,110, caregivers cost).  The 
proportion of indirect costs became more significant as the level of disability increased (see subgroup 
of individuals with SPMS and PPMS characterised by steady deterioration in function vs. RRMS usually 
accompanied by periods of partial or complete recovery over several weeks).  People with SPMS had 
the most substantial burden due to incurring both high medical and non-medical costs and greater 
disability compared with peoples with RRMS. More details are presented in Figures 4 and 5 (excluding 
Romanian data, where unit costs were not available).  
 
Figure 3: The preferred source of information for PWMS 
 
Intangible costs - Quality of life, wellbeing and disability. The average utility score (based on EQ-5D-
5L) was 0.60 (60% of perfect health), with a loss of 0.25 (25%) compared with the general population. 
Utility varied across countries: Germany reported the highest mean utility (0.77; 77% of perfect 
health) and lowest utility loss compared with the general population (9%); France, Romania and the 
UK presented the lowest values for utility (49%, 51%, and 54% of perfect health, respectively) and the 
highest utility loss compared with the general population (34%, 35% and 32%, respectively). The 
majority of the individuals reported that they were independent (did not need help with daily living), 
36.8%, or mildly dependent, 48.5%.  Disability levels varied across country case studies: Germany 
reported the lowest levels of disability (only 10% moderately dependent; 0% severely dependent); the 
UK presented the highest levels of disability (26% were moderately dependent or severely 
dependent). The subgroups of individuals with PPMS and SPMS reported more severe disability and 
greater loss in utility compared with the RRMS group. Overall, the utility scores for PWMS were lower 
than those obtained for the general population in each country. More details on the specific case 
studies and MS types are presented in Figures 6-9.  
                                                          
n Standard deviation. 
0% 10% 20% 30% 40% 50% 60% 70%
MS specific websites
Family doctor
MS magazines or publications
Health websites
Online forums
Social media
Online support groups
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Figure 4: Tangible costs: Average annual costs per person by country (€, 2014-15)   
(All sample and country case studies) 
   
 
Figure 5: Tangible costs: Average annual costs per person with MS (€, 2014-15)  
(By type of MS) 
 
Relapsing remitting multiple sclerosis (RRMS); Secondary progressive multiple sclerosis (SPMS); Primary 
progressive multiple sclerosis (PPMS). Differences across countries were statistically significant at 0.05 
except “Direct non-medical costs” and “Consultations”. All differences in the total, direct medical/non-
medical and indirect costs were statistically significant across MS types. 
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Satisfaction with the healthcare service received. Overall 69% of the individuals were satisfied/very 
satisfied with the healthcare service received. The majority of individuals who reported to be 
satisfied/very satisfied were from USA (76%) and France (75%); in the UK, Germany and Romania only 
about half of the respondents reported to be satisfied/very satisfied with the service received (52%, 
56% and 57% respectively).  Individuals with PPMS were likely to be less satisfied with the service 
received compared with people with RRMS and SPMS. More details on the specific case studies and 
MS types are presented in Figures 8 and 9. 
 
Figure 6: Intangible costs – Utility (EQ-5D-5L measure) and disability (Barthel index) in PWMS by 
country 
(All sample and individual countries)  
 
 
Figure 7: Intangible costs – Utility (EQ-5D-5L measure) and disability (Barthel index) in PWMS by 
type of MS 
(Types of MS) 
 
Primary progressive multiple sclerosis (PPMS); Secondary progressive multiple sclerosis (SPMS); Relapsing remitting multiple 
sclerosis (RRMS). Utility (mean) - All differences were statistically significant across countries and MS types. Disability (Mean) 
- Differences were not statistically significant across countries; Differences across MS types were statistically significant at 
0.05. Utility values vary between 0 (dead)—1 (full health). Barthel index values vary between 0 (severely dependent) to 20 
(independent). 
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Figure 8: Intangible costs: Utility (EQ-5D-5L) and satisfaction with the healthcare received by 
country 
(All sample and individual countries) 
 
 
 
Figure 9: Intangible costs: Utility (EQ-5D-5L) and satisfaction with the healthcare received by type 
of MS 
(Types of MS) 
  
Note: Satisfaction with the healthcare service was ranked on a scale from 0 to 10. The following categories were 
considered for analysis: not satisfied/indifferent (0-6); satisfied (7-8); very satisfied (9-10). Differences were 
statistically significant across countries and types of MS. 
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5.1.5. Health status aspects valued by PWMS 
The health status aspects that are particularly important to PWMS are reported in Figure 10. A series 
of aspects, including mobility, usual activities or pain/discomfort, are commonly valued when using 
generic utility measure (such as EQ-5D-5L), whereas fatigue and weakness, balance and dizziness, or 
bladder problems are specific aspects that respondents raised as they felt these were not adequately 
addressed by EQ-5D-5L. The six aspects reported above also represent the most recurrent factors that 
changed over the course of the illness. Respondents also stated that their change had a significant 
impact on the quality of their life.  MS-related complications, such as bladder infections, fractures and 
falls (due to balance problems, reduced mobility, weakness and fatigue, as well as joint pain) are major 
reasons for concerns and respondents believed a new MS treatment should keep them under control. 
 
Figure 10: Health status aspects valued by PWMS  
 
 
5.1.6 Access to MS treatment  
Primary data from PWMS showed easier access to MS treatments in European countries compared to 
North America. More precisely, in North America the main factors impeding access to MS treatments 
were low reimbursement rate for DMTs (14%) and lack of prompt disease diagnosis (29%).  In Europe, 
reimbursement rates for DMTs were higher than 90% (among all countries), apart from Romania 
(81%). Early diagnosis was a barrier in all case studies. Germany reported the lowest rate of early 
diagnosis (24%) whereas Romania reported the highest (61%).  Availability of MS neurologists 
appeared to be a potentially impeding factor in the UK and Romania, which both had the lowest rate 
of MS neurologists (64%) compared to all other countries. Overall, Germany ranked first in our “easy 
access to MS treatment” country ranking scale; it accumulated the highest percentages (>70%) among 
the majority (4 out of 6) of factors affecting access to MS treatment. Following are France, UK, 
Romania and USA. Other studies in the literature attempted to value access to MS treatment across 
EU country settings and used similar factors to the ones considered in our study (Table 3). Our results 
were consistent with findings from previous studies that equally ranked France and Germany as best 
performers compared with the UK and Romania.6,7  
0% 10% 20% 30% 40% 50% 60%
Mobility
Fatigue & Weakness
Balance Problems & Dizziness
Usual activities (e.g. Work, study, housework, Family or
leisure activities)
Pain / discomfort
Bladder problems
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Table 3: Access to MS treatments in selected countries 
Factors affecting access to MS 
specific treatments 
USA UK France Germany Romania Source 
       
Clinical management of MS 
Diagnosis (received early diagnosis) 
 
Availability of MS treatment guidelines  
(clinician utilization) 
 
Availability of MS specific neurologists 
(annual PWMS utilization) 
29% 56% 53% 24% 61% 
Primary data analysis 
from this study 
AAN 
ABN 
NICE 
HAS EMSP EMSP 
Primary data analysis 
from this study [6 ] 
87% 64% 70% 90% 64% 
Primary data analysis 
from this study 
Reimbursement  
(reimbursed by NHS) 
14% 92% 95% 92% 81% 
Primary data analysis 
from this study 
Affordability of DMTs  
(utilisation of DMTs among treatment-
eligible PWMS) 
66% 56% 53% 70% 41% 
Primary data analysis 
from this study 
Availability of MS registries or 
databases 
n/a n/a n/a 93.5% n/a 
[6 ] 
 
Country rankings for access to MS 5 3 2 1 4 
The authors of the 
report based on 
primary data analysis 
from this study  
 n/a 4 2 1 3 [6 ] 
 n/a 3 1 2 4 [7 ] 
Note: Affordability is measured as utilisation of DMTs from treatment eligible PWMS. AAN = American 
Association of Neurology; ABN= Association of British Neurologists; NICE= National Institute for Health and 
Care Excellence; HAS = Haute Autorité de Santé; EMSP= European Multiple Sclerosis Platform. 
 
5.2 Primary data analysis: Caregivers 
5.2.1 Caregivers: Responses and sociodemographic data   
Fifty four responses were received, 22% (12/54) of which were suitable for analysiso. The majority of 
individuals were females (67%, 8), with an average age of 51 yrs. About 75% of individuals were the 
spouse of a person with MS, and had cared for a person with MS for an average of 8 years. About 67% 
of respondents were employed and for about 50% of caregivers in employment, caring for the person 
with MS meant some work-related problem in the previous 12 months. Given the limited sample size 
and poor completion rates of the questions, the analysis covered the few socio economic aspects 
reported below.  
5.2.2 Caregivers: Costs and quality of life 
The average indirect costs to informal caregivers in the previous year were €31,155 (only productivity 
loss data were reported; 50% (n=4) (Table 4). The average time spent by a non-professional caregiver 
                                                          
o Blank/partially completed questionnaires were not considered for analysis. 
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in caring for a person with MS was 22.4 hours per week. Respondents reported an average utility of 
0.70 (utility loss of 0.15 compared with the general population; EQ-5D-5L score). The majority of the 
caregivers felt no (83%) or mild burden (17%) because of their status as a caregiver. Caregiver costs, 
quality of life, and how they feel are compared with data from the PWMS survey. Caregiver costs 
related to productivity losses are about double the cost reported by PWMS, whereas they reported 
better quality of life compared with PWMS (70% vs. 60% of perfect health). Both caregivers and the 
person they are caring for reported a mild level of discomfort / disability.  
 
Table 4: Caregiver costs, quality of life, and how they feel (compared with people with MS 
[PWMS]) 
 Caregivers PWMS 
Total annual indirect costs related to 
productivity loss:  
Mean (standard deviation)  
 
 
€31,155 (€32,945) 
 
 
€16,061 (€4,833) 
EQ-5D-5L utility:  
Mean (standard deviation) 
[explanation] 
 
0.70 (0.19) 
[70% of perfect health] 
 
0.60 (0.12) 
[60% of perfect health] 
How they feel/level of disability 
The majority of caregivers 
felt no (83%) or mild burden 
(17%) because of their status 
as caregiver 
The majority of PWMS reported 
low levels of disability 
(independent, 37%; mildly 
dependent 12%) 
 
5.3 Primary data analysis: Clinicians 
5.3.1 Responses and sociodemographic data   
Thirty seven clinicians were contacted; 43% of them (16/37) returned the online survey (87%, 14/16) 
or were interviewed (12%, 2/16). Overall, 12 experts returned data suitable for analysis (32%, 12/37). 
The majority of the respondents were male (71%; 5/7) with an average age of 43 years.p The countries 
of practice included: Italy (2), Spain (2), UK (2), USA (2), France (1), Denmark (1), Germany (1) and 
Greece (1). Seven respondents reported on the training they had received as follows: two in general 
neurology; five received MS specialist training. The average number of years in practice after 
completing all medical training was 16, and the practice settings included: community hospital (one 
case), university hospital (5 cases), and private hospital (one case).  
 
5.3.2 Diagnosis and treatment 
The majority of their patients experienced the first MS symptom when they were 20-30 years old 
(67%) and received a diagnosis of MS between 20-30 years old (42%; 5/12), or later (31-40 years old, 
58%; 7/12). The majority of clinicians reported a gap between diagnosis and treatment of less than 2 
months (67%, 8/12). Table 5 compares clinician and PWMS views on diagnosis and treatment.  
 
                                                          
p Please note that only 7 individuals reported their demographic data. 
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Table 5: Diagnosis and treatment: Clinician and PWMS views 
 What clinicians said What PWMS said 
When their patients/they 
themselves experienced the first 
MS symptom  
70% -the majority of their patients 
experienced the first MS symptom 
aged 20-30 years  
Average of 30.4 
years old 
Age at diagnosis of most patients 
58% - 31-40 years old 
42% - 20-30 years old 
Average of 35.2 
years old 
Delay between first symptoms and 
MS diagnosis  
58% - 1 year or more  Average of 4.8 years 
Delay between diagnosis and 
treatment with DMTs 
67% - Within 2 months  Average 1.9 years* 
Note: * PWMS were not asked explicitly about their delay between diagnosis and treatment. The age 
they started treatment (calculated as difference between their current age and the number of years 
on DMTs) was then subtracted from the age of their diagnosis. 
 
5.3.3 Treatment recommendations for MS 
Choosing DMTs. Effectiveness, tolerability, safety and PWMS’ preferences are the most important 
attributes for clinicians when choosing among DMTs. The clinicians reported that their patients had 
similar reasons for choosing a DMT (Table 6). PWMS put greater value on aspects such as convenience, 
doctor’s advice and safety compared with clinicians.  
When would clinicians use DMTs?  The majority of clinicians treated SPMS with DMTs only in the 
presence of relapses (88%, 7/8; Table 7). About 92% (11) of clinicians did not consider starting 
treatment with DMTs when a person has a normal MRI, as they considered it unnecessary at this stage. 
They would consider starting treatment with DMTs only in the presence of brain lesions, optic neuritis 
or severe initial relapse. They would consider reviewing the person every: 4-6 months (clinical review), 
3-6 months (blood analysis); 12 months (MRI). 
Treating PWMS with oral DMTs. 75% of clinicians were treating PWMS with oral DMTs (9/12) whereas 
about 55% of the PWMS reported that they were treated with DMTs. One clinician who did not treat 
PWMS with DMTs reported that oral DMTs are: less convenient, less efficacious, and more expensive 
than injectable DMTs.  
Switching DMTs. Just over half of the clinicians (57%) reported that they may vary the waiting time 
before switching a patient to another DMT according to the individual clinical situation. 
Discontinuation of DMT. More than half of clinicians (57%) reported that between 10-30% of 
individuals discontinue the use of their DMT within 6 years. However, it was not possible to clarify the 
precise reason(s) for discontinuation (e.g. treatment stops working).  
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Table 6: Treatment with DMTs: Clinician views compared with those of PWMS 
 What the clinicians said What the clinicians said 
drove PWMS’ decisions 
What the PWMS said 
Choosing DMTs: the 
most important 
three attributes 
are… 
Effectiveness  
Safety 
Tolerability 
Effectiveness  
Safety 
Tolerability 
Convenience (25%) 
Doctor’s advice (19%) 
Other* (19%) 
Tolerability (17%) 
Effectiveness (14%) 
Treating PWMS with 
oral DMTs  
75% were treating their 
patients with oral DMTs 
n/a 
54.9% were treated 
with DMTs 
Switching DMTs  
For 57% of respondents 
the waiting time before 
switching the patients to 
another first- or second-
line DMT may vary 
according to the clinical 
situation of the PWMS 
n/a 
30% switched from 
one DMT to another 
Note: *Other factors reported: side effects (i.e. safety), do not currently take/want to take any 
medications. 
 
Table 7: When would clinicians use DMTs? 
People with … Yes Comments 
… secondary progressing multiple 
sclerosis (SPMS)  
88% 
Depending on the presence of 
relapses 
… a normal MRI  
8% (unnecessary at 
this stage) 
Only in the presence of brain lesions, 
optic neuritis or severe initial relapse 
… an MRI reporting 1 or more non-
enhancing lesions  
77% 
Either with injectable (100%) or orals 
(80%) (multiple choice) 
 
 
Treating a person when they have an MRI reporting 1 or more non-enhancing lesions. About 77% of 
clinicians would consider starting the treatment with DMTs (44% definitely yes; 33% maybe) either 
with injectable medicines (100%, 5/5) or orals (80%; 4/5). The presence of a series of risk factors 
(number and site of MRI lesions, oligoclonal bands on CSF, clinical presentation) was reported as the 
main reason to start treatment with DMTs. About 50% (2/4) would consider reviewing the person 
every 1-3 months (as first visit), then every six months; the other half would consider an annual review.  
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6. An analysis of HTAs for MS therapies and the factors 
influencing decision-making in different settings 
6.1 Coverage decisions for MS therapies across countries  
Despite their systematic nature, HTA decision-making processes and evidence differ significantly 
across countries and this may lead to different coverage recommendations for MS medicines. This is 
further confirmed by our database (Table 8) in which none of the nine study medicines received 
homogenous recommendations in the HTA settings studied in this report.  
All the medicines shown in Table 8 had homogenous indication for the treatment of relapsing–
remitting multiple sclerosis (RRMS) across the countries considered. The recommendations were 
divided into three categories: a) listed (L), b) listed with restrictions of the medicine to a subgroup of 
the population or under certain conditions (LWC), and c) do not list [reject] (DNL).  
 
6.2 Main criteria leading to HTA recommendations across countries 
A number of criteria drive value assessments in MS treatments across countries. These are outlined 
and compared in this section and help explain some of the disagreements in the recommendations 
shown in Table 8.  
6.2.1 Clinical trials and comparators  
About 51% of all clinical studies considered across all six agencies (n=113) were phase III trials 
(designed to assess the effectiveness of the new intervention and, thereby, its value in clinical practice 
in comparison with the current best alternative treatment), followed by indirect comparisons (31%) 
designed to compare interventions using data from separate studies; and other types of trials (18%) 
such as extension of the primary trials (n=9 across the entire sample) phase II trials (n=7 across the 
entire sample) and marketing surveillance studies (n=4). The comparators most commonly used for 
the trials were: beta-interferons or other DMTs (57%) or placebo (43%) (see Appendix Figure 2).   
6.2.2 Clinical endpoints used in the trials  
Substantial differences were seen in the number of primary and secondary endpoints (or measures) 
extrapolated by the studied agencies. The disparities seen may be explained by differences in trials 
reported, a different level of detail in reporting the same clinical trials, as well as a different number 
of subgroups and interim analyses considered (see Appendix Figure 3). For instance, in the case of 
alemtuzumab, NICE reported 22 primary endpoints whereas SMC, TLV and CADTH reported only 
seven, four and two primary endpoints, respectively. By contrast, in the case of teriflunomide, NICE, 
TLV and CADTH included a mixed treatment comparison that compared the study medicine with each 
of the treatments in the decision problem (beta interferons, glatiramer acetate, natalizumab and 
fingolimod). This was not considered by the other agencies and therefore led to a difference in the 
total number of endpoints across the agencies for teriflunomide. 
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6.2.3 Safety 
The proportion of cases with adverse events (AEs) reported was higher in the cases of SMC and HAS 
compared with NICE. The rate of treatment discontinuations was more commonly reported by HAS 
and CADTH compared to SMC, IQWIG and NICE (Appendix Figure 4). 
 
Table 8: Treatment recommendations for MS  
Molecule name 
(branded name) 
Indication 
considered 
Evidence from HTA agencies 
  NICE 
(UK) 
TLV 
(Sweden) 
HAS 
(France) 
SMC 
(Scotland) 
IQWIG 
(Germany) 
CADTH 
(Canada) 
IFNβ 1a IM 
(Avonex) 
RRMS DNL DNL LWC LWC N/A N/A 
Alemtuzumab 
(Lemtrada) 
Active relapsing–
remitting multiple 
sclerosis 
L L N/A L N/A DNL 
IFNβ 1a SC 
(Rebif) 
RRMS DNL L LWC DNL N/A DNL 
IFNβ 1b SC 
(Betaferon, 
Extavia) 
RRMS N/A L LWC N/A N/A N/A 
Glatiramer 
acetate 
(Copaxone) 
RRMS DNL N/A L N/A N/A N/A 
Teriflunomide 
(Aubagio) 
RRMS LWC L L LWC A DNL 
Dimethyl 
fumarate 
(Tecfidera) 
Active relapsing-
remitting multiple 
sclerosis 
LWC LWC LWC L A N/A 
Fingolimod 
(Gylenia) 
Highly active 
relapsing–remitting 
multiple sclerosis 
LWC L LWC LWC A LWC 
Natalizumab 
(Tysabri) 
Rapidly evolving 
severe relapsing–
remitting multiple 
sclerosis (RES). 
L L LWC DNL N/A LWC 
Notes: RRMS=relapsing remitting multiple sclerosis; L= Listed (accepted); LWC= Listed with criteria (restricted); DNL= Do not list (rejected); 
A= assessed without decision. N/A = not appraised for the indication; NICE=National Institute for Health and Care Excellence (England); 
TLV=Dental and Pharmaceutical Benefits Board (Sweden); HAS=Haute Autorité de Santé (France); SMC=Scottish Medicines Consortium 
(Scotland); IQWiG=Institute for Quality and Efficiency in Healthcare (Germany); CADTH=Canadian Agency for Drugs and Technologies in 
Health (Canada). 
 
6.2.4 HRQoL 
HRQoL evidence was reported and considered differently across the various agencies and the number 
of quality of life endpoints varied across agencies. Only in two cases were multiple sclerosis-specific 
measures used: for fingolimod, the PRIMUS (Patient Reported Outcome Indices for Multiple Sclerosis); 
and for natalizumab the MSQLI (Multiple Sclerosis Quality of Life Inventory). The most widely used 
generic measures (total n=36) were: EQ-5D-5L utility measure (50%; n=18) and the 36-Item Short Form 
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Health Survey (SF-36; 17%; n=6). In the remaining cases (33%; n=12) the measure used was not 
specified. Interestingly, and in the case of teriflumide only, the HRQoL data was considered by all study 
agencies and measured using the same tool (SF-36 and EQ-5). 
6.2.5 Economic evidence 
Only NICE, SMC, TLV and CADTH assessed the cost-effectiveness of each study medicine.  Across all 
the agencies a total of 21 economic evaluation studies were reported:  76% (n= 16) of the studies were 
cost-utility analyses; 19% (n=4) were cost-minimisation analyses; and one study was a cost-
effectiveness analysis. In the case of NICE only cost-utility models were reported. An interesting case 
is teriflunomide where SMC and TLV considered a cost-minimization analysis, whereas NICE and 
CADTH considered a similar cost-utility model. Between TLV and SMC there was a different 
comparator considered in the cost-minimization analysis, as SMC considered beta-interferon or 
glatiramer acetate whereas TLV considered only interferon 1-b. These assessments were associated 
with differing outcomes (listed with restriction by NICE, TLV and SMC, but rejected by CADTH).  
Uncertainties  
Each agency raised a number of concerns about the clinical and economic evidence presented by the 
manufacturer. Using an iterative approach, we collected all types of uncertainty across the entire 
sample by agency.  
 Uncertainties around the reliability of the treatment’s clinical benefit were raised most often by 
NICE (n=12 total number of uncertainties across nine appraisals), CADTH (n=6 uncertainties across 
five appraisals) and TLV (n=3 total number of uncertainties across eight appraisals). These were 
followed by uncertainties surrounding study design, which were mostly raised by SMC (n=8 total 
number of uncertainties across seven appraisals), IQWiG (n=5 total number of uncertainties across 
three appraisals) as well as NICE (n= 6 total number of uncertainties across nine appraisals). SMC 
also placed a lot of emphasis on issues around the study population (n=6) whereas safety and data 
issues were commonly raised by CADTH (n=5), SMC (n=3 total number of uncertainties across nine 
appraisals) and HAS (n=3). 
 Uncertainties related to the economic evidence were divided in two broad categories: first, 
uncertainties around the economic model were most commonly raised by NICE (n=52 
uncertainties across nine appraisals); CADTH (n=21 uncertainties across five appraisals); SMC 
(n=24 total number of uncertainties across seven appraisals) and TLV (n= 9 uncertainties across 
eight appraisals). The uncertainties most frequently raised across all the agencies related to the 
clinical assumptions in the evidence. Other types of uncertainties included, for example, the type 
of modelling, type of costs, type of effects, and possible variation in the ICER.  (Appendix Figure 5). 
Second, uncertainties raised around the clinical evidence used for the economic evaluation were 
more frequently raised by NICE, TLV and CADTH. The three agencies included uncertainties around 
the estimates of clinical benefit (e.g. if the benefits of oral treatment were captured by the 
dimethyl fumarate model) followed by concerns around the study comparators or other factors 
such as the comparator used, the conduct and design of the trial, etc. (Appendix Figure 6).  
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6.2.6 Stakeholder input 
Input from external stakeholders played an important role in shaping the HTA assessments across HTA 
bodies. In particular, when looking at both the interpretation of the evidence (see “clinical 
uncertainties”) and the “other considerations “ criteria, their input was reported 183 times (across all 
the appraisals examined in the 6 countries).  With the exception of HAS and IQWIG where there is no 
clear presence of any external stakeholder opinion, the stakeholder input was considered across 
agencies in England, Scotland, Sweden and Canada. In 67% of cases (n=123) the HTA assessments 
considered input from clinical experts, in 20% (n=37) from PWMS, and 13% (n=24) from non-specified 
experts. 
6.2.7 Time lag between regulatory approval and HTA completion 
The time between a medicine receiving regulatory approval and the completion of an assessment was 
similar for HTA assessments conducted by TLV, HAS and SMC (the lag times are 61.5 months, 54 
months, and 58 months, respectively). The median lag time for NICE was 21 monthsq whereas for 
IQWIG it was 6.6 months (Appendix Table 7). 
6.2.8 Other considerations  
A series of additional elements (considerations) were identified and considered across HTA 
assessments, beyond the clinical, safety and economic evidence.  Their impact on the final decision 
was reviewed and they were classified into two main categories: first, elements related to the disease 
and second, elements related to the treatment. Overall 142 “other considerations” were identified 
across a total of 26 health technology assessments; 51% of other considerations (n= 72) related to 
disease characteristics, whereas 49% (n=70) covered treatment characteristics. The most common 
considerations related to the disease raised by all agencies included: the nature of the disease 
affecting the individual (77% of the HTA assessments); and the financial and emotional burden created 
by the disease on the family and their caregivers (65%). NICE and CADTH raised particular concerns on 
the ability to work (64% and 58%, respectively) and the financial burden created by the disease (61% 
and 60%, respectively). Other considerations related to the treatment characteristics included: 
adverse events of the treatment alternatives and the possible advantages from new oral medicines. 
 
                                                          
q Please note that time lapse between marketing authorisation and completion of the HTA appraisal was longer for 
interferons (2002), whereas for the other DMTs (from 2006 onwards) the appraisal system changed and the time lags 
decreased. More details are in appendix 12.    
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7. Using primary and secondary evidence to inform 
policy change in MS 
7.1 What the PWMS and caregiver surveys suggest about policy 
change in MS 
7.1.1 Estimating and comparing the costs, HRQoL and experience reported by PWMS and 
caregivers across settings  
The primary analysis of the PWMS and caregiver data sets provided updated international data on the 
burden of MS they experience as well as their HRQoL/experience of care when novel DMTs are 
available in clinical practice. The evidence collected covered the following key issues: 
Experience of MS treatment with DMTs 
The majority of PWMS had experience of MS treatment with DMTs from the start of their treatment; 
slightly more than half of the PWMS were currently receiving DMTs. Results were comparable with a 
similar survey conducted in the USA70. 
Starting treatment early at the point of clinical diagnosis 
PWMS are aware of the potential side effects of treatments and may prefer to delay possible risks as 
much as possible; however when they discuss the irreversible effect of MS on brain volume and the 
attached disabilities with their clinician they may opt for an early intervention.  
Sharing information with the PWMS 
It is important from the outset to give patients accurate information on what to expect from treatment, 
including the evidence that DMT efficacy can be only partial, moderate and non-curative (Association 
of British Neurologists 2015)56. Patients should also discuss the potential risk as well as expected 
benefit of treatment; monitoring requirements; possible future disabilities; and work, family and other 
factors that are personally important. Clinicians should take account of their views when 
recommending a personalised treatment selection. More research is needed to further investigate 
stakeholder views on changing MS management practices to include early intervention.  
Experiences of MS-management 
The primary care data analysis of the clinician survey gave the opportunity to compare PWMS and 
clinician experiences of MS-management, to identify whether their views on MS management are 
aligned with patients’ and to explore the factors that influence these views. Results from the PWMS 
survey showed that half of the respondents preferred to make the final decision about their 
management of care. Whether a PWMS becomes engaged in their care is a choice for the individual, 
but clinicians and other stakeholders recognise that this should be strongly promoted given the derived 
health benefits to the PWMS and their increased satisfaction71. 
The preferred source of information for PWMS 
The preferred source of information for PWMS is the internet (MS-specific sites as well as social media 
or support group sites) and clinicians; this is also confirmed in the literature58,70. Whether a person is 
newly-diagnosed or has had MS for a long time, information available from the media (particularly 
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social media) can be overwhelming, and many PWMS may be unsure of where to look for the 
information they need. While the Internet can be a vast source of information about MS, it can also be 
a source of inaccurate, biased, or confusing information. It is important that people can filter the 
content as needed and patient organisations have an important role to play in providing information 
to support shared decision making, including conveying the importance of early treatment1.  
Economic burden of the disease (tangible costs) 
Total average annual PWMS costs were €40,313. Just over half of total average costs (€20,631) were 
associated with direct medical costs (medicines, consultations with a specialist, hospitalisations), 
followed by indirect costs such as loss of productivity (€16,061) and direct non-medical costs (€2,127), 
which reflect caregiver costs.  The proportion of indirect costs became more significant as the level of 
disability increased. Results from similar surveys with PWMS conducted in Europe and elsewhere63,72 
reported comparable total costs across countries, although medication costs contributed a smaller 
proportion compared with the results presented here. Crucially, previous surveys did not account for 
expensive pharmacological developments in MS management such as dimethyl fumarate, fingolomid 
and alemtuzumab.  
The overall costs (and relative ratio between direct and indirect costs) varied also according to the type 
of MS and severity of the disease. More severe and disabling cases of SPMS were characterised by 
increased total costs (€48,000) where indirect costs accounted for the majority (about 65%) compared 
with RRMS (about €41,000) where indirect costs accounted for about 36%. Results were similar to 
international evidence in the literature62,73.  
Socio economic burden of the disease on PWMS (intangible costs) 
The average utility value reported was 0.60 (60% of perfect health) based on EQ-5D-5L, with a loss of 
25% compared with the general population. Utilities varied across healthcare systems (USA as well as 
Germany reported greater levels compared with other countries) and types of MS. Comparable 
estimates were found elsewhere8,72. 
Greater values in utility were accompanied by lower disability and increased satisfaction values with 
the healthcare service received. However in a few country settings (e.g. France and Romania) lower 
levels of disability and increased satisfaction with the healthcare service were accompanied by a 
noticeable decrease in utility compared with the general population. It can be argued that other health 
state factors beyond EQ-5D-5L63 are (more) important to PWMS. If their improvement is missed by EQ-
5D-5L this can be showcased by other indicators (increased satisfaction with the service and decreased 
disability).  
Valuing health outcomes beyond EQ-5D-5L 
If the clinical focus for MS has relied heavily on the measurement of disability, more recently the 
importance of MS outcome assessment from the perspective of the individual with MS has been 
recognized74. Patient relevant outcome measures (PROMs) include information provided by the 
individual that reflects their functioning health and well-being from their perspective, including how 
the disease and medical interventions impact on their quality of life. The diverse subjective symptoms 
associated with loss of quality of life are difficult to quantify, hence discrepancies arise between the 
perceptions of PWMS and their physicians concerning which domains of health are the most 
important. 
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The challenge of using generic measures of quality of life in people with a specific health condition 
such as MS is recognised as they may not capture all of the domains that are impacted by the 
condition. If important domains are missing from the generic measures, the value derived will be 
higher than the real impact creating invalid comparisons across interventions and populations. 
Integrating PROMs into clinical practice has the potential to capture those benefits and understand 
them better. Results from the survey reported fatigue and weakness, bladder or balance problems as 
the most frequently reported factors that changed over the course of their illness. Respondents stated 
also that their change had a significant impact on their life and believed a new MS treatment should 
keep them under control. Evidence from the literature75 showed that MS-related complications, 
typically severe urinary tract infections, constipation, fractures and falls (due to increased weakness 
and fatigue), and pressure sores are major reasons for hospital admissions with important 
socioeconomic consequences. This highlights the importance of identifying the most appropriate 
utility measure to be adopted. 
Socio economic burden of MS on caregivers 
While sampling issues prevented the production of robust results on caregiving, the findings may 
provide a preliminary understanding of the differences in socioeconomic burden between PWMS and 
their caregivers.  The total annual indirect costs related to productivity loss for caregivers were about 
€31,000, almost double those reported by PWMS (€16,000).  
 
7.1.2 Exploring the impact that a paradigm shift in the management of MS could have on 
health outcomes and resource utilisation 
The primary analysis of the PWMS allowed an exploration of the economic impact of introducing 
earlier interventions in the disease pathway. Subgroup analysis compared individuals who received 
early diagnosis of MS (≤12 months from first symptoms) with individuals who received diagnosis later 
than 12 months after the first symptoms. The cut-off of 12 months adopted here followed current 
guidance recommending that initiation of a DMT within 12 months of a single neurological attack with 
MRI-enhancing lesions should be considered as a promising, preventative strategy against future 
accumulation of disability52,56,76,77. Analysis of the data collected from the PWMS showed that patients 
treated earlier in the course of the disease showed a trend towards lower total (€38,185 vs. €42,058), 
indirect (€15,390 vs. €18,521) and DMT (€18,942 vs. €20,044) costs and a higher VAS score (65 vs. 62) 
compared to those receiving late treatment, although these differences were not statistically 
significant (p>0.05). Reflecting on our study sample, even though our results suggest that a shift 
towards early treatment had comparable effects to late treatment in terms of overall costs and health 
outcomes, a larger sample of respondents followed over time would be needed to generate more 
robust conclusions on the long-term socioeconomic impact of early DMT initiation. Importantly, using 
real world data on a larger scale across international settings would be crucial to better understand 
the impact of a paradigm shift in the management of MS on long-term productivity loss in different 
healthcare systems. This could also provide robust results to inform country specific, as well as 
international, policy developments. Healthcare systems need to be able to respond dynamically as 
new evidence emerges on the diagnosis and treatment of MS, along with more evidence on the 
psychosocial support requirements for PWMS, and the long-term economic evidence on the impact 
of MS. 
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7.1.3 Using the economic and socioeconomic data from this to create a health benefit design 
package for PWMS in the countries of interest 
Value-based benefit design (VBBD)78 advocates better alignment between copayment and clinical 
value. The rationale behind VBBD is that many valuable treatments for chronic illnesses, such as MS 
medications, are often used sub-optimally, potentially leading to undesirable outcomes such as an 
increase in complications and avoidable hospitalizations (e.g. falls, urinary tract infections). 
Copayment should be reduced to improve clinical outcomes for high-value therapy such as DMTs. In 
the long run, the improved clinical outcomes may translate into cost savings in terms of reduction in 
hospitalization events, disabilities, absenteeism, presenteeism, and overall direct and indirect 
costs79,80. Direct and socioeconomic cost data from the PWMS survey can be used to inform policy 
change in the way a health care system views a debilitating chronic disease such as MS.  
 
7.2 What the Clinician survey suggests about policy change in MS 
The primary analysis of the PWMS and clinician data sets provided evidence on whether the views of 
PWMS and treating physicians are aligned on MS management and allowed the exploration of factors 
which influence these views.  
7.2.1  Diagnosis and treatment 
Both PWMS and clinicians reported that PWMS experience a first symptom of MS at about 20-30 
years, whereas they receive formal diagnosis of MS at 30-40 years old. Mixed views were reported 
when commenting on the delay between first symptoms and diagnosis (1 year for the clinicians vs. 5 
years for PWMS) and the delay between diagnosis and treatment with DMTs (2 months vs. 2 years, 
respectively). When looking at treatment management, about 75% of the clinicians were treating their 
patients with oral DMTs whereas only 55% of the PWMS reported that they were treated with DMTs. 
Current clinical guidance suggests that some clinicians may consider starting DMT treatment for 
individuals within 12 months after first symptoms if MRI establishes evidence of MS diagnosis (2010 
McDonald criteria)21. However factors such as poor rates of clinician adherence to treatment 
guidelines, relative lack of available neurologists and low treatment affordabilitymay explain the 
longer delays in access to treatment as reported by PWMS58.  
When choosing a DMT, the most important attributes for clinicians are effectiveness, safety and 
tolerability (and they believed that similar aspects drove PWMS’ decisions). PWMS, on the other hand, 
placed greater value on convenience, doctor’s advice and safety. Responses showed that safety and 
efficiency data may be valued by clinicians and PWMS in their choice of treatment. A lack of long-term 
safety and efficacy data for the newer DMTs may have led to conservatism among some clinicians and 
PWMS regarding initiating treatment with a DMT1. 
7.2.2 When treatment should be started 
 In line with current guidance about 92% (11) of clinicians did not consider starting treatment with 
DMTs in a person with a normal MRI as they considered it unnecessary at that stage. They would 
consider starting treatment with DMTs only in the presence of brain lesions, optic neuritis or severe 
initial relapse. The PWMS had mixed views on the matter; for example, they were aware of the side 
effects of treatments and preferred to delay possible risks as much as possible; but they were also 
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knowledgeable about the irreversible effect of MS on brain volume and the attached disabilities.  The 
individual personal circumstances, variability in access to relevant information on MS and individual 
involvement in the decision making process appeared to be the driving factors in MS management. 
Those factors may give reasons for promoting joint decision for both patients and clinicians 1.  
 
7.3  What does the analysis of HTAs suggest about policy change in 
MS 
Evidence from the analysis of HTA assessments showed that input from external stakeholders is 
already part of the HTA decision making in different country settings. Stakeholder input from patient 
associations was more commonly considered by NICE compared to other HTA agencies.  Key 
stakeholders should be actively engaged by those conducting HTAs, and have their views reflected in 
the HTA process81 . The key messages extrapolated from the evidence included the following: 
 There is a need for a standardized approach when including PWMS’ views in HTA decision 
making.  Given that MS is a disease that can have a profound impact on the HRQoL of PWMS, the 
HTA bodies should pay particular attention in their assessments on the HRQoL factors. The HTAi 
Interest Group on Patient and Citizen Involvement in HTA (PCIG) has developed a patient group 
submission template that is available for people to use82. 
 Greater homogeneity across HTA bodies is needed when taking into account HRQoL elements.  
 Health gain and quality of life data should take account of dimensions that patients say have a 
significant impact on their daily lives; many of these items are not captured by the generic tools 
(e.g. EQ-5D-5L) often used by HTA agencies internationally. 
 There is a need for standardized approaches when including “other factors” in HTA decision 
making and a wide range of evidence and outcomes must be considered. A wide array of 
considerations and assessments related to the clinical and economic evidence are considered in 
HTA assessments across case studies and DMTs of interest.  Appropriate guidelines and systematic 
approaches to evidence synthesis and analysis during an HTA assessment is important, particularly 
when more complex statistical and methodological techniques are used to address gaps in the 
available data for a technology81 . HTA assessments should take account of the items patients say 
have a significant impact on their daily lives; however, many of these items are not captured by 
generic tools such as the EQ-5D-5L questionnaire. 
 Moving beyond HTAs and leveraging the potential of risk-sharing to improve cost-effectiveness 
and affordability.  HTA assessments can have a substantive impact on access to DMTs for PWMS. 
Specifically for England and Scotland, fingolimod was originally not recommended by NICE and 
SMC, respectively, and the decision was only reversed after a patient access scheme was 
introduced. This data is confirmed by the literature6.  
 Discussion on an earlier use of DMTs to reduce accumulation of irreversible long term damage 
and decrease socioeconomic burden is missing from HTA assessment. The lack of real world data 
on the clinical and economic benefits of the technology is a key issue commonly reported by HTA 
bodies81. The literature on MS management reported a lack of evidence on long term clinical and 
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economic benefit of DMTs as these treatments have only recently been introduced into clinical 
practice and the collection of such data is currently under way. 
 HTA assessments should be conducted in a timely manner. The collection of long-term benefit of 
DMTs using real world evidence is a necessary step forward and currently underway but should 
not inflict unwanted delays to HTA decision-making.  
 
8. The way forward for MS management: achieving 
better outcomes for PWMS 
MS is associated with a high cost of illness, both in terms of direct and indirect costs.  Given that the 
onset of MS is generally in early adult life and the disease lasts over an individual’s lifetime, there are 
huge costs relating to productivity losses. In addition, there is a clear deterioration in health outcomes 
of PWMS and their caregivers in comparison to the healthy population, with impact potentially 
increasing in line with the severity of the disease. The primary data analysis from this study expanded 
previous knowledge on the socioeconomic burden and health related quality of life (HRQoL) of PWMS 
and their caregivers across country settings. Results confirmed that there is an urgent need to achieve 
better outcomes for people with MS and the evidence suggests that this is possible if policy makers 
address a series of issues to secure the following three main goals: 
(1) improve the quality of care and health outcomes for every person with MS; 
(2) generate further robust evidence to inform decision making; 
(3) increase responsiveness of health care systems to new evidence on MS. 
 
8.1 Improve the quality of care and health outcomes for every 
person with MS: Diagnosis, treatment and management goals should 
be set to provide the best health outcome for every person with MS 
8.1.1 Early diagnosis and treatment  
Although it seems entirely plausible that early diagnosis and treatment with DMTs would help reduce 
relapse rates and MRI lesion accumulation and, therefore, would favourably influence the long-term 
prognosis, they have been only recently introduced in MS management and there are no published 
and peer-reviewed controlled trial results showing long-term benefit. Therefore, the harmonised 
collection of real world data with the support of national registries is urgently needed; analysis of 
this data will allow clarification of the benefit of early diagnosis and treatment with DMTs on long-
term outcomes. 
8.1.2 More intense monitoring regimens should be routinely available in practice  
Understanding of MS disease activity has developed significantly over the past 15 years. This can 
largely be attributed to improved use of MRI scanning, which provides a more sensitive tool for 
identifying inflammatory damage in MS.  MRI is an effective way of capturing disease activity early 
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and it is increasingly used in practice; this was confirmed by the clinicians participating in this study. 
Ongoing debate also considers the use of MRI to monitor disease activity in patients on DMTs. Current 
recommendations on ‘treating to target’ mean ‘treat until no evidence of disease activity is reached’, 
including no relapses, no increase in disability and no new or active (enhancing) lesions on patients’ 
MRI scans. Meeting this objective implies regular monitoring of not only clinical relapse and disability 
progression, but also MRI activity. Regular use of MRI to monitor disease activity and the effects of 
treatment is still not common practice (for example see the UK1), though it is increasingly used as an 
outcome measure for clinical trials and the sample of clinicians interviewed confirmed that MRI is 
routinely available in their practice across different country settings. Therefore, more research is 
needed to measure the effectiveness of more intense monitoring with more frequent MRI scans. 
Updated and internationally comparable evidence on the use of diagnostic imaging as a means of 
capturing disease activity should be generated as a priority. Registry data should be amended to 
allow for collection and use of standardised information on MRI use across countries to better 
monitor diagnosis and treatment goals across settings. 
8.1.3 MS management  
Current clinical guidance suggests that some clinicians may consider starting DMT treatment for 
individuals within 12 months after first symptoms appear if MRI establishes evidence of MS diagnosis 
(2010 McDonald criteria) 21.  In this report the majority of the clinicians interviewed were treating their 
patients with oral DMTs whereas only half the PWMS reported that they were treated with DMTs.  
There seem to be a number of barriers in accessing treatment, for example, delays in diagnosis, lack 
of available neurologists, poor adherence to clinical guidelines by clinicians and problems with DMT 
reimbursement by a number of national health systems. Although the incidence and intensity of these 
barriers is not the same across settings, they reflect the PWMS views reported in this paper. Given 
perceived uncertainties around efficacy, risk and tolerability, limitations in prescribing guidelines and 
access to treatment, the treatment decision is quite often “no treatment”. For example in UK there is 
a preference to “wait and see”, with less frequent prescribing compared to other countries, 
particularly early in the disease course83.   
PWMS mentioned that they were aware of the side effects of individual treatments and preferred to 
delay potential risks as much as possible; but they were also knowledgeable about the irreversible 
effect of MS on brain volume and the attached disabilities.  The individual personal circumstances, 
variability in access to relevant information on MS and individual involvement in the decision 
making process appeared to be the driving factors in MS management and shared decision making 
may be more satisfactory for both patients and clinicians. Health systems should involve more 
actively PWMS in decisions about their disease management.   
8.1.4 Better evaluation of the health outcomes for PWMS and their caregivers 
The use of generic measures of utility such as EQ-5D-5L in people with MS does not capture all of the 
domains that are impacted by the condition. The primary data from PWMS presented in the report 
sought to address this issue and to evaluate which health status aspects are particularly important to 
PWMS beyond EQ-5D-5L. Many of these items (e.g. fatigue and weakness, balance and dizziness, or 
bladder problems) are not captured by the generic tools (e.g. EQ-5D-5L) often used by HTA agencies 
internationally.  
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There is some evidence in the literature and from our analysis that the socioeconomic burden and 
distress on caregivers is substantial, and it varies by the PWMS’ level of disability, but more robust 
evidence is needed to elucidate the full impact of MS on caregivers and the overall family across 
countries. Given that MS is a disease that can have a profound impact on the HRQoL of both PWMS 
and their caregivers, the HTA bodies should pay particular attention in their assessments on the 
HRQoL factors and consider a wider range of evidence and outcomes beyond EQ-5D for PWMS. 
8.2 (Further) robust evidence should be generated and used in order to make 
appropriate decisions about care management MS strategies 
8.2.1 MS registries  
MS registries act as a powerful instrument for population level measurements of disease specific 
characteristics, long-term benefits of DMTs and dissemination of information about treatments and 
services in a given region. Unfortunately, most of the registries do not collect harmonised 
epidemiological, clinical, economic and utility data on PWMS across countries.  This lack of data can 
affect the quality of the evidence available and possible estimation of the impact of management 
strategies on economic and health outcomes. For example, in the UK, there is no complete national 
registry of people with MS18, whereas in Germany and Sweden databases exist which cover more than 
90% of the MS population19. The European Register for Multiple Sclerosis (EUReMS) demonstrated 
that international MS data collection is possible and has the potential to lead to better outcomes for 
those living with multiple sclerosis in Europe107. More robust epidemiological, clinical and disease 
management data are needed internationally to inform better decisions for priority setting and 
healthcare policy in MS. 
8.2.2 HTA evidence 
Key stakeholders should be actively engaged by those conducting HTAs in order to understand 
stakeholder perspectives on the HTA process. Health gain and quality of life data should take account 
of dimensions that patients say have a significant impact on their daily lives; many of these items are 
not captured by generic tools often used by HTA agencies internationally (e.g. EQ-5D-5L 
questionnaire). There is a need for a standardized approach when including PWMS’ views in HTA 
decision-making and assessments should take account of dimensions that patients say have a 
significant impact on their daily lives. 
Greater consistency is needed in collecting economic data and evaluating the economic impact of MS 
to ensure that comparisons across settings can be made. Health gain and quality of life data in HTA 
assessments should incorporate appropriate standardized methods for economic evaluations and 
grading evidence.   
 
8.3 Increase responsiveness of health care systems to new evidence on MS 
Although guidelines for MS management are available at local and international levels there is still 
limited use of standardized protocols across settings and this has been confirmed by the clinicians 
participating in this study. Widespread adoption of current guidelines would avoid inappropriate 
variations in eligibility for DMT initiation across local settings84 and strengthen diagnosis, treatment 
and monitoring.  Finally, a reward system should be in place across healthcare systems to improve 
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clinical practice (quality of care and health outcomes) and incorporate updated harmonised 
evidence on MS management (available from MS registries) into health care decision-making.   
 
 
37 
 
9.  References  
 
1. MS Society Time to Act – September 2015. A consensus on early treatment. 
2. Dutta R, Trapp BD. Pathogenesis of axonal and neuronal damage in multiple sclerosis. 
Neurology. 2007;68(22 Suppl 3):S43-54. 
3. Scalfari A, Neuhaus A, Daumer M, Muraro PA, Ebers GC. Onset of secondary progressive phase 
and long-term evolution of multiple sclerosis. J Neurol Neurosurg Psychiatry. 2014;85(1):67-
75. 
4. Leray E, Yaouanq J, Le Page E, et al. Evidence for a two-stage disability progression in multiple 
sclerosis. Brain. 2010;133(Pt 7):1900-1913. 
5. Warren S WKGWHO, 2001. Multiple Sclerosis. ISBN: 92-4-156203-X. 2001. 
6. Wilsdon T., Barron A., Mitchell-Heggs A., Ginoza S. Access to medicines for multiple sclerosis: 
Challenges and opportunities. Charles Rivers Associates, February 2014.  Available online at: 
http://www.crai.co.uk/sites/default/files/publications/CRA-Biogen-Access-to-MS-
Treatment-Final-Report.pdf. 
7. Kobelt and Kasteng. Access to innovative treatments in multiple sclerosis in Europe, a report 
prepared for the European Federation of Pharmaceutical Industry Associations (EFPIA). 2009. 
Available at: 
http://www.comparatorreports.se/Access%20to%20MS%20treatments%20-%20October%2
02009.pdf  
8. Trisolini M HA, Wiener J, Lesesne S. Global Economic Impact of Multiple Sclerosis. Multiple 
Sclerosis International Federation UK, London, United Kingdom. 2010. 
9. Goodin DS, Frohman EM, Garmany GP, Jr., et al. Disease modifying therapies in multiple 
sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the 
American Academy of Neurology and the MS Council for Clinical Practice Guidelines. 
Neurology. 2002;58(2):169-178. 
10. Tremlett H, Yousefi M, Devonshire V, Rieckmann P, Zhao Y. Impact of multiple sclerosis 
relapses on progression diminishes with time. Neurology. 2009;73(20):1616-1623. 
11. Fox RJ, Hersh CM. Multiple sclerosis. Cleveland Clinic Disease Management Project. The 
Cleveland Clinic Foundation. Published June 2014.  
http://www.clevelandclinicmeded.com/medicalpubs/diseasemanagement/neurology/mults
clerosis/multsclerosis.htm. Accessed April 29, 2015. 
12. Lublin FD, Reingold SC, Cohen JA, et al. Defining the clinical course of multiple sclerosis: the 
2013 revisions. Neurology. 2014;83(3):278-286. 
13. Goodin DS, Reder AT, Ebers GC, et al. Survival in MS: a randomized cohort study 21 years after 
the start of the pivotal IFNbeta-1b trial. Neurology. 2012;78(17):1315-1322. 
14. Mackenzie IS, Morant SV, Bloomfield GA, MacDonald TM, O'Riordan J. Incidence and 
prevalence of multiple sclerosis in the UK 1990-2010: a descriptive study in the General 
Practice Research Database. J Neurol Neurosurg Psychiatry. 2014;85(1):76-84. 
15. Hoer A, Schiffhorst G, Zimmermann A, et al. Multiple sclerosis in Germany: data analysis of 
administrative prevalence and healthcare delivery in the statutory health system. BMC Health 
Serv Res. 2014;14(381):1472-6963. 
16. Kingwell E, Marriott JJ, Jette N, et al. Incidence and prevalence of multiple sclerosis in Europe: 
a systematic review. BMC Neurol. 2013;13(128):1471-2377. 
17. Pugliatti M, Rosati G, Carton H, et al. The epidemiology of multiple sclerosis in Europe. Eur J 
Neurol. 2006;13(7):700-722. 
18. Trust. M. A to Z of MS. Types of MS. Available online at 
http://www.nationalmssociety.org/What-is-MS/Types-of-MSPrevalence and incidence of 
multiple sclerosis http://www.mstrust.org.uk/atoz/prevalence_incidence.jsp. . 2013. 
Accessed February 20, 2015. . 
 
 
38 
 
19. MSIF. The Atlas of MS 2013, Mapping multiple sclerosis around the world. Available at 
http://www.atlasofms.org/./ 2013. 
20. Finkelsztejn A, Gabbai AA, Fragoso YD, et al. Latin American algorithm for treatment of 
relapsing-remitting multiple sclerosis using disease-modifying agents. Arq Neuropsiquiatr. 
2012;70(10):799-806. 
21. Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 
revisions to the McDonald criteria. Ann Neurol. 2011;69(2):292-302. 
22. Cutter GR, Zimmerman J, Salter AR, et al. Causes of death among persons with multiple 
sclerosis. Mult Scler Relat Disord. 2015;4(5):484-490. 
23. Shirani A, Zhao Y, Karim ME, et al. Association between use of interferon beta and progression 
of disability in patients with relapsing-remitting multiple sclerosis. Jama. 2012;308(3):247-
256. 
24. Giovannoni. blog (http://multiple-sclerosis-research.blogspot.com/2015/06/early-
intervention-in-ms.html). 2015  
25. Banwell B, Giovannoni G, Hawkes C, Lublin F. Editors' welcome and a working definition for a 
multiple sclerosis cure. Mult Scler Relat Disord. 2013 Apr;2(2):65-7. doi: 
10.1016/j.msard.2012.12.001. Epub 2013 Jan 21. 
26. J.M. WHLaS. Multiple Sclerosis: Diagnosis and Therapy. Wiley-Blackwell by John Wiley & Sons. 
2012. 
27. Kappos L, Antel J, Comi G, et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N 
Engl J Med. 2006;355(11):1124-1140. 
28. O'Connor P, Wolinsky JS, Confavreux C, et al. Randomized trial of oral teriflunomide for 
relapsing multiple sclerosis. N Engl J Med. 2011;365(14):1293-1303. 
29. Kappos L, Gold R, Miller DH, et al. Efficacy and safety of oral fumarate in patients with 
relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-
controlled phase IIb study. Lancet. 2008;372(9648):1463-1472. 
30. Goodin DS, Bates D. Treatment of early multiple sclerosis: the value of treatment initiation 
after a first clinical episode. Mult Scler. 2009;15(10):1175-1182. 
31. Kappos L, Freedman MS, Polman CH, et al. Effect of early versus delayed interferon beta-1b 
treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year 
follow-up analysis of the BENEFIT study. Lancet. 2007;370(9585):389-397. 
32. Johnson KP, Brooks BR, Ford CC, et al. Glatiramer acetate (Copaxone): comparison of 
continuous versus delayed therapy in a six-year organized multiple sclerosis trial. Mult Scler. 
2003;9(6):585-591. 
33. Comi G. Clinically isolated syndrome: the rationale for early treatment. Nat Clin Pract Neurol. 
2008;4(5):234-235. 
34. Jacobs LD, Beck RW, Simon JH, et al. Intramuscular interferon beta-1a therapy initiated during 
a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med. 
2000;343(13):898-904. 
35. Comi G, De Stefano N, Freedman MS, et al. Comparison of two dosing frequencies of 
subcutaneous interferon beta-1a in patients with a first clinical demyelinating event 
suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial. Lancet Neurol. 
2012;11(1):33-41. 
36. Comi G, Filippi M, Barkhof F, et al. Effect of early interferon treatment on conversion to 
definite multiple sclerosis: a randomised study. Lancet. 2001;357(9268):1576-1582. 
37. Comi G, Martinelli V, Rodegher M, et al. Effect of glatiramer acetate on conversion to clinically 
definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a 
randomised, double-blind, placebo-controlled trial. Lancet. 2009;374(9700):1503-1511. 
38. Jeffrey. TOPIC: Teriflunomide delays clinically definite MS. 
www.medscape.com/viewarticle/803177. 2013. 
 
 
39 
 
39. Gold R, Wolinsky JS, Amato MP, Comi G. Evolving expectations around early management of 
multiple sclerosis. Ther Adv Neurol Disord. 2010;3(6):351-367. 
40. Filippi M, Rovaris M, Inglese M, et al. Interferon beta-1a for brain tissue loss in patients at 
presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, 
placebo-controlled trial. Lancet. 2004;364(9444):1489-1496. 
41. Rieckmann P. Neurodegeneration and clinical relevance for early treatment in multiple 
sclerosis. Int MS J. 2005;12(2):42-51. 
42. Gout O, Lebrun-Frenay C, Labauge P, Le Page GE, Clavelou P, Allouche S. Prior suggestive 
symptoms in one-third of patients consulting for a "first" demyelinating event. J Neurol 
Neurosurg Psychiatry. 2011;82(3):323-325. 
43. Putzki N, Fischer J, Gottwald K, et al. Quality of life in 1000 patients with early relapsing-
remitting multiple sclerosis. Eur J Neurol. 2009;16(6):713-720. 
44. Salter AR, Cutter GR, Tyry T, Marrie RA, Vollmer T. Impact of loss of mobility on instrumental 
activities of daily living and socioeconomic status in patients with MS. Curr Med Res Opin. 
2010;26(2):493-500. 
45. Scott TF, Schramke CJ. Poor recovery after the first two attacks of multiple sclerosis is 
associated with poor outcome five years later. J Neurol Sci. 2010;292(1-2):52-56. 
46. Fernandez O, Fernandez V, Arbizu T, et al. Characteristics of multiple sclerosis at onset and 
delay of diagnosis and treatment in Spain (the Novo Study). J Neurol. 2010;257(9):1500-1507. 
47. Kingwell E, Leung AL, Roger E, Duquette P, Rieckmann P, Tremlett H. Factors associated with 
delay to medical recognition in two Canadian multiple sclerosis cohorts. J Neurol Sci. 
2010;292(1-2):57-62. 
48. Kelly SB, Chaila E, Kinsella K, et al. Multiple sclerosis, from referral to confirmed diagnosis: an 
audit of clinical practice. Mult Scler. 2011;17(8):1017-1021. 
49. Miller RM, Happe LE, Meyer KL, Spear RJ. Approaches to the management of agents used for 
the treatment of multiple sclerosis: consensus statements from a panel of U.S. managed care 
pharmacists and physicians. J Manag Care Pharm. 2012;18(1):54-62. 
50. Giovannoni G, Nath A. After the storm: neurofilament levels as a surrogate endpoint for 
neuroaxonal damage. Neurology. 2011 Apr 5;76(14):1200-1. doi: 
10.1212/WNL.0b013e3182143345. Epub 2011 Feb 23. 
51. Giovannoni G. Cerebrospinal fluid neurofilament: the biomarker that will resuscitate the 
'Spinal Tap'. Mult Scler. 2010;16(3):285-286. 
52. Castrop F, Haslinger B, Hemmer B, Buck D. Review of the pharmacoeconomics of early 
treatment of multiple sclerosis using interferon beta. Neuropsychiatr Dis Treat. 2013;9:1339-
1349. 
53. http://www.euroqol.org/. 
54. Collin C, Wade DT, Davies S, Horne V, The Barthel Index, Disability and Rehabilitation 2008, 
10:2 61-63. 
55. Zarit SH, Reever KE, Bach-Peterson J. Relatives of the impaired elderly: correlates of feelings 
of burden. Gerontologist. 1980;20(6):649-655. 
56. Scolding N, Barnes D, Cader S, et al. Association of British Neurologists: revised (2015) 
guidelines for prescribing disease-modifying treatments in multiple sclerosis. Pract Neurol. 
2015;15(4):273-279. 
57. Nicod E, Kanavos P. Developing an evidence-based methodological framework to 
systematically compare HTA coverage decisions: A mixed methods study. Health Policy. 
2016;120(1):35-45. 
58. Holloway E, Redford-Totts D (MS Society). Right Treatment, right time? How people with MS 
make decisions about disease modifying drugs http://www.treatmerightms.org.uk/wp-
content/ uploads/2014/04/Right-treatment-right-time.pdf. 
59. Giovannoni G. Any evident MRI T2-lesion activity should guide change of therapy in multiple 
sclerosis--yes. Mult Scler. 2015;21(2):134-136. 
 
 
40 
 
60. Giovannoni G, Nath A. After the storm: neurofilament levels as a surrogate endpoint for 
neuroaxonal damage. Neurology. 2011;76(14):1200-1201. 
61. WHO. Worl Health Organization. Health statistics and information systems database, Disease 
burden, Available via 
http://www.who.int/healthinfo/global_burden_disease/estimates/en/index2.html. 
62. Ashaye. Multiple Sclerosis and Variation in Health Utilities: A Systematic Review of the 
Literature. Conference: 2014 Joint ACTRIMS-ECTRIMS Meeting, At Boston, Massachusetts 
USA,. 2014. 
63. Kobelt G, Berg J, Lindgren P, Fredrikson S, Jonsson B. Costs and quality of life of patients with 
multiple sclerosis in Europe. J Neurol Neurosurg Psychiatry. 2006;77(8):918-926. 
64. Adelman G, Rane SG, Villa KF. The cost burden of multiple sclerosis in the United States: a 
systematic review of the literature. J Med Econ. 2013;16(5):639-647. 
65. Kolasa K. How much is the cost of multiple sclerosis--systematic literature review. Przegl 
Epidemiol. 2013;67(1):75-79. 
66. Pike. Poster from the 1st European Academy of Neurology (EAN) Congress, Berlin June 2015 
(http://www.eaneurology.org/berlin2015/uploads/media/Biogen.pdf). 2015. 
67. Naoshy. Poster from the 1st European Acadmy of Neurology Congress, Berlin June 2015  
68. Sidovar MF, Limone BL, Lee S, Coleman CI. Mapping the 12-item multiple sclerosis walking 
scale to the EuroQol 5-dimension index measure in North American multiple sclerosis 
patients. BMJ Open. 2013;3(5). 
69. Goldman MD, Motl RW, Rudick RA. Possible clinical outcome measures for clinical trials in 
patients with multiple sclerosis. Ther Adv Neurol Disord. 2010;3(4):229-239. 
70. Available at: http://multiplesclerosis.net/ms-in-america-2014/. 
71. Available at: http://multiplesclerosis.net/ms-in-america-2014/. 
72. Kobelt G, Berg J, Atherly D, Hadjimichael O. Costs and quality of life in multiple sclerosis: a 
cross-sectional study in the United States. Neurology. 2006;66(11):1696-1702. 
73. Naci H, Fleurence R, Birt J, Duhig A. Economic burden of multiple sclerosis: a systematic review 
of the literature. Pharmacoeconomics. 2010;28(5):363-379. 
74. Rieckmann P, Boyko A, Centonze D, et al. Achieving patient engagement in multiple sclerosis: 
A perspective from the multiple sclerosis in the 21st Century Steering Group. Mult Scler Relat 
Disord. 2015 May;4(3):202-218. doi: 10.1016/j.msard.2015.02.005. Epub 2015 Mar 2.; 2015. 
75. Marrie RA, Elliott L, Marriott J, et al. Dramatically changing rates and reasons for 
hospitalization in multiple sclerosis. Neurology. 2014;83(10):929-937. 
76. Broadley SA, Barnett MH, Boggild M, et al. A new era in the treatment of multiple sclerosis. 
Med J Aust. 2015;203(3):139-141. 
77. Noyes K, Weinstock-Guttman B. Impact of diagnosis and early treatment on the course of 
multiple sclerosis. Am J Manag Care. 2013;19(17 Suppl):s321-331. 
78. Chernew ME, Rosen AB, Fendrick AM. Value-based insurance design. Health Aff. 
2007;26(2):30. 
79. Mahoney JJ. Reducing patient drug acquisition costs can lower diabetes health claims. Am J 
Manag Care. 2005;11(5 Suppl):S170-176. 
80. Goldman DP, Joyce GF, Karaca-Mandic P. Varying pharmacy benefits with clinical status: the 
case of cholesterol-lowering therapy. Am J Manag Care. 2006;12(1):21-28. 
81. Available at: https://www.ispor.org/workpaper/International-survey-of-methods-used-in-
HTA.pdf. 
82. http://www.htai.org/interest-groups/patient-and-citizen-involvement.html Aa. 
83. MS Society. A lottery of treatment and care – MS Services across England at the UK, 2013. 
Available at: http://mslottery.mssociety.org.uk/wpcontent/uploads/2013/04/UK-ms-
lottery.pdf. 
84. Pozzilli C, Romano S, Cannoni S. Epidemiology and current treatment of multiple sclerosis in 
Europe today. J Rehabil Res Dev. 2002;39(2):175-185. 
 
 
41 
 
85. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease 
progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research 
Group (MSCRG). Ann Neurol. 1996;39(3):285-294. 
86. Group PPoRaDbIb-aSiMSS. Randomised double-blind placebo-controlled study of interferon 
beta-1a in relapsing/remitting multiple sclerosis. . Lancet. 1998;352(9139):1498-1504. 
87. Paty DW, Li DK. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI 
analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC 
MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group. Neurology. 
1993;43(4):662-667. 
88. Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves 
disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-
blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology. 
1995;45(7):1268-1276. 
89. Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of 
natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354(9):899-910. 
90. Cohen JA, Coles AJ, Arnold DL, et al. Alemtuzumab versus interferon beta 1a as first-line 
treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled 
phase 3 trial. Lancet. 2012;380(9856):1819-1828. 
91. O'Connor PW, Li D, Freedman MS, et al. A Phase II study of the safety and efficacy of 
teriflunomide in multiple sclerosis with relapses. Neurology. 2006;66(6):894-900. 
92. Gold R, Kappos L, Arnold DL, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing 
multiple sclerosis. N Engl J Med. 2012;367(12):1098-1107. 
93. Multiple sclerosis: management of multiple sclerosis in primary and secondary care. NICE 
2014. 
94. Multiple sclerosis study group [GRESEP]. Guidelines for the treatment of MS  
95. Guidelines from The Italian Neurological and Neuroradiological Societies for the use of 
magnetic resonance imaging in daily life clinical practice of multiple sclerosis patients (2013). 
Neurol Sci. 2013. 
96. Guidelines on the clinical use for the detection of neutralizing antibodies (NAbs) to IFN beta 
in multiple sclerosis therapy: report from the Italian Multiple Sclerosis Study group Neurol Sci. 
2014. 
97. Gold R, Oreja-Guevara C. Advances in the management of multiple sclerosis spasticity: 
multiple sclerosis spasticity guidelines. Expert Rev Neurother. 2013;13(12 Suppl):55-59. 
98. German Association of Neurologists guidelines for the diagnosis and treatment of MS 
eurologie DGf: Diagnostik Und Therapie Der Multiplen Sklerose. Leitlinien Für Diagnostik Und 
Therapie in Der Neurologie. Stuttgart: Georg Thieme Verlag; 2013. . 
99. Freedman MS, Selchen D, Arnold DL, et al; Canadian Multiple Sclerosis Working Group. 
Treatment optimization in MS: Canadian MS Working Group updated recommendations. Can 
J Neurol Sci. 2013. 
100. American Academy of Neurology Neurology 2014 available at https://www.aan.com. 
101. European Academy of Neurology (European Federation of Neurological Societies) 2011. 
102. Multiple sclerosis: EFNS guidelines on the use of imaging in multiple sclerosis: M. Filippi et al.; 
European handbook of neurological management: volume 1, 2nd edition. Edited by N. E. 
Gilhus, M. P. Barnes and M. Brainin. 2011 Blackwell Publishing Ltd. 
103. Multiple sclerosis: EFNS guidelines on the use of anti-interferon beta antibody measurements 
in multiple sclerosis: P. S. Sørensen et al.; European handbook of neurological management: 
volume 1, 2nd edition. Edited by N. E. Gilhus, M. P. Barnes and M. Brainin. 2011 Blackwell 
Publishing Ltd. . 
104. Multiple sclerosis relapses: efns guidelines on acute relapses of multiple sclerosis: f. Sellebjerg 
et al.; European handbook of neurological management: volume 1, 2nd edition. Edited by N. 
E. Gilhus, M. P. Barnes and M. Brainin. 2011 Blackwell Publishing Ltd. 
 
 
42 
 
105. The European MS Platform's Code of Good Practice 2008 , 2010  
106. Kantarci O, Wingerchuk D. Epidemiology and natural history of multiple sclerosis: new 
insights. Curr Opin Neurol. 2006;19(3):248-254. 
107. The EUReMS project website, available from http://eurems.eu/index.php/project-backgroud. 
 
 
43 
 
10. Appendices  
Appendix Table 1:  Main DMTs - Platform therapies  
 Molecule name Branded name Introduced 
to market 
Administration Efficacy Main side effects Recommendations
/indications from 
the literature 
 Interferons interferon  
β-1a 
Rebif (EMD Serono, 
Inc) 
1998 Injectable (SC 
thrice weekly) 
Reduction of 32% in 
RR, 37% in DP, 52% 
compared to 
placebo85  
flu-like side-effects 
(myalgias, 
headache, malaise) 
Active non 
aggressive RRMS 
(first line), SPMS 
with exacerbations, 
CIS Avonex (Biogen) 1996 Injectable (IM 
once weekly) 
Reduction of 32% in 
RR, 31% in DP 
compared to 
placebo86  
interferon  
β-1b 
Betaferon (Bayer); 
Extavia (Novartis) 
1993 Injectable (SC 
every other day) 
Reduction of 34% in 
RR, 29% in DP 
compared to 
placebo87  
Glatiramer acetate (GA) Copaxone (Teva 
Pharmaceuticals) 
1996 Injectable (SC  
daily) 
Reduction of 29% in 
RR, 12% in DP 
compared to 
placebo88  
skin injection site 
reactions, 
lipoatrophy 
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Appendix Table 2:  Main DMTs - Non-platform therapies  
Molecule name Branded name Introduced to 
market 
Administratio
n 
Efficacy Main side effects Recommendations
/indications from 
the literature 
Infusion Mitoxantrone Novantrone 
(EMD Serono) 
2000 Infusion at a 
hospital 
 Cardiotoxicity and 
leukemia 
In US: active non 
aggressive RRMS 
(second line), SPMS 
with exacerbations 
Natalizumab Tysabri (Biogen) 2004 
(reintroduced 
2006) 
Infusion every 
28 days 
Reduction of 68% in 
RR, 42% in DP 
compared to placebo89  
Progressive 
multifocal 
leukoencephalopath
y (PML) 
Active non 
aggressive RRMS 
(second line), 
aggressive RES MS 
Alemtuzumab Lemtrada  
(Genzyme) 
2012 Infusion twice 
yearly 
Reduction of 50-55% in 
RR and 42% in DP 
compared to βIFNs90 
Thrombocytopenic 
purpura (ITP), 
thyroid problems 
Active non 
aggressive RRMS 
(first line) 
Oral 
agents 
Fingolimod Gilenya 
(Novartis) 
2010 Oral (once 
daily) 
Reduction of 54% in 
RR, 30% in DP 
compared to placebo27 
Bradycardia and 
atrioventricular 
block. Few cases of 
PML reported 
Active non 
aggressive RRMS 
(second line), 
aggressive RES MS 
Teriflunomide Aubagio 
(Genzyme) 
2012 Oral (once 
daily) 
Reduction of 30% in 
RR, 30% in DP 
compared to placebo91 
Hepatic irritation and 
alopecia 
Active non 
aggressive RRMS 
(first line) 
Dimethyl 
fumarate, 
(BG-12) 
Tecfidera 
(Biogen) 
2013 Oral (twice 
daily) 
Reduction of 53% in 
RR, 38% in DP 
compared to placebo92 
Flushing and 
gastrointestinal 
symptoms. Few 
cases of PML 
reported 
Active non 
aggressive RRMS 
(first line) 
SC= subcutaneous, IM=intramuscular, II= intravenous infusion, RR= relapse rate, DP=disability progression 
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Appendix Table 3: MS guideline across country settings 
Country  Country specific 
guideline  
Reference 
England yes 
Association of British Neurologists: revised (2015) guidelines 
for prescribing disease-modifying treatments in multiple 
sclerosis BMJ 201556 
 
Multiple sclerosis: management of multiple sclerosis in 
primary and secondary care. NICE 201493 
France yes 
Multiple sclerosis study group [GRESEP]. Guidelines for the 
treatment of MS94  
Sweden no See European guidance below 
Italy yes 
Guidelines from The Italian Neurological and 
Neuroradiological Societies for the use of magnetic resonance 
imaging in daily life clinical practice of multiple sclerosis 
patients (2013). Neurol Sci. 201395 
 
Guidelines on the clinical use for the detection of neutralizing 
antibodies (NAbs) to IFN beta in multiple sclerosis therapy: 
report from the Italian Multiple Sclerosis Study group Neurol 
Sci. 201496 
Germany yes 
Gold et al. Advances in the management of multiple sclerosis 
spasticity: multiple sclerosis spasticity guidelines. Expert Rev 
Neurother. 201397 
 
German Association of Neurologists guidelines for the 
diagnosis and treatment of MS eurologie DGf: Diagnostik Und 
Therapie Der Multiplen Sklerose. Leitlinien Für Diagnostik 
Und Therapie in Der Neurologie. Stuttgart: Georg Thieme 
Verlag; 2013.98  
Romania no 
See European guidance. The European MS Platform's Code of 
Good Practice 
Canada yes 
Freedman MS, Selchen D, Arnold DL, et al; Canadian Multiple 
Sclerosis Working Group. Treatment optimization in MS: 
Canadian MS Working Group updated recommendations. Can 
J Neurol Sci. 201399 
USA yes 
American Academy of Neurology Neurology. 2014100 
 
Summary of Evidence-Based Guideline: Complementary and 
Alternative Medicine in Multiple Sclerosis  
 
Assessment and Management of Psychiatric Disorders in 
Individuals with Multiple Sclerosis  
European 
guidelines 
yes 
European Academy of Neurology (European Federation of 
Neurological Societies) 2011101 
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Country  Country specific 
guideline  
Reference 
Multiple sclerosis: EFNS guidelines on the use of imaging in 
multiple sclerosis: M. Filippi et al.; European handbook of 
neurological management: Volume 1, 2nd edition. Edited by 
N. E. Gilhus, M. P. Barnes and M. Brainin. 2011 Blackwell 
Publishing Ltd.102 
 
Multiple sclerosis: EFNS guidelines on the use of anti-
interferon beta antibody measurements in multiple 
sclerosis: P. S. Sørensen et al.; European handbook of 
neurological management: Volume 1, 2nd edition. Edited by 
N. E. Gilhus, M. P. Barnes and M. Brainin. 2011 Blackwell 
Publishing Ltd.103  
 
Multiple sclerosis relapses: EFNS guidelines on acute 
relapses of multiple sclerosis: F. Sellebjerg et al.; European 
handbook of neurological management: Volume 1, 2nd 
edition. Edited by N. E. Gilhus, M. P. Barnes and M. Brainin. 
2011 Blackwell Publishing Ltd.104 
  
 
The European MS Platform's Code of Good Practice 2008 , 
2010105  
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Appendix Table 4: Total annual costs and utility per PWMS by country 
 
Countries Total direct 
medical costs  
Mean (SD) 
Total direct 
non-medical 
costs Mean (SD) 
Total indirect costs 
Mean (SD) 
Total costs 
Mean (SD) 
Utility  (EQ-
5D-5L) 
Utility 
lost  
Original data, 
publication 
date  
UK (Euro, 
2006 
exchange 
rate) 
EDSS 0–3: €4,577 (3,057) 
[£6,714 (4,484)] 
EDSS 4–5:  
€5,524 (3,594) 
[£8,101 (5,271)] 
EDSS 6–8:  
4,131 (3,897) 
[£6,059 (5,716)] 
EDSS 0–3:  
€1,304 (5,043) 
[£1,913 (7,396)] 
EDSS 4–5:  
€7,022 (8,303) 
[£10,299 (12,178)] 
EDSS 6–8:  
28,121 (20,514) 
[£41,242 (30,086)] 
EDSS 0–3:  
€2,191 (4,562) 
[£3,214 (6,691)] 
EDSS 4–5:  
€5,110 (6,184) 
[£7,494 (9,069)] 
EDSS 6–8:  
€7,989 (6,583) 
 [£11,717 (9654)] 
EDSS 0–3:  
€8,074 (9,060) 
[£11,841 (13,288)] 
EDSS 4–5:  
€17,656 (11,872) 
[£25,894 (17,411)] 
EDSS 6–8:  
€40,241 (23,479) 
[£59,018 (34,435)] 
EDSS 2.0:  
0.725 
EDSS 6.5:  
0.477 
0.27 2006 data 
from [72]  
 
UK 2012 
(£ 2009)  from 
[61] 
France 
(Euro) 
All: €23,654 (32,494) 
EDSS 0–3: €11,806 (13,514) 
EDSS 4–5: €19,817(20,845) 
EDSS 6–8: €38,774 (44,518) 
All: €20,730 (27,123) 
EDSS 0–3: €12,250 
(22,541) 
EDSS 4–5: €24,306 
(27,959) 
EDSS 6–8: €27,666 
(28,698) 
All: €44,384 (45,687) 
 
EDSS 0–3: 
0.686 
(0.217) 
EDSS 4–5: 
0.520 
(0.238) 
EDSS 6–8: 
0.333 
(0.283) 
0.28 2006 data 
from [72]  
 
France 2009  
from [61] 
Sweden 
(Euro) 
All: €15,186 (24,638) All: €21,264 (45,056) All: €17,151 (18,497) All: €53,601 (58,108) EDSS 2.0: 
0.696 
EDSS 6.5:  
0.462 
0.23 2006 data 
from [72]  
Sweden 2006  
from [61] 
Italy (Euro) EDSS 0–3: €21,418 
(13,719) 
EDSS 4–5: €30,507 
(23,868) 
EDSS 6–8: €13,646 
(21,141) 
EDSS 0–3: €447 (2007) 
EDSS 4–5: €5634 
(8,874) 
EDSS 6–8: €15,826 
(10,260) 
EDSS 0–3: €596 
(2,737) 
EDSS 4–5: €5,185 
 (8,134) 
EDSS 6–8: €10,120 
(11,686) 
EDSS 0–3: €22,461 (13,799) 
EDSS 4–5: €41,327 (31,263) 
EDSS 6–8: €39,592 (37,785) 
EDSS 2.0: 
0.677 
EDSS 6.5: 
0.477 
0.31 2006 data 
from [72]  
 
Italy 2012 
(Euro 2009) 
from [61] 
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 Total direct 
medical costs  
Mean (SD) 
Total direct 
non-medical 
costs Mean (SD) 
Total indirect costs 
Mean (SD) 
Total costs 
Mean (SD) 
Utility  (EQ-
5D-5L) 
Utility 
lost  
Original data, 
publication 
date  
Germany 
(Euro) 
EDSS 0–3: €16,954 
(9,886) 
EDSS 4–5: €17,841 
(12,458) 
EDSS 6–8: €30,348 
(24,911) 
EDSS 0–3: €1,163 (3,629) 
EDSS 4–5: €12,373 
(21,513) 
EDSS 6–8: €22,926 
(16,515) 
EDSS 0–3: €3,057 
(8,938) 
EDSS 4–5: €9710 
(15,789) 
EDSS 6–8: €10,996 
(16,940) 
EDSS 0–3: €21,174 (16,287) 
EDSS 4–5: €39,923 (33,335) 
EDSS 6–8: €64,270 (15,472) 
EDSS 2.0: 
0.721 
EDSS 6.5: 
0.440 
0.2 2006 data 
from [72]  
2012 (Euro 
2009)  from 
[61] 
Canada 
(Euro, 2012 
exchange 
rate) 
EDSS 0 – 3:  
€25,476 (62,182) 
[CAN$ 19,837 (48,419)] 
EDSS 4 - 6.5:  
€18,054 (15,421) 
[CAN$ 14,058 (12,008)]  
EDSS 7 – 9:  
€12,172 (12,785) 
[CAN$  9,478 (9,955)]  
EDSS 0 – 3:  
€4,942 (13,732) 
[CAN$ 3,848 (10,693)]  
EDSS 0 – 3:   
€16,325 (26,805) 
[CAN$ 12,712 (20,872)] 
EDSS 7 – 9:  
€56,535 (69,873) 
[CAN$  4,4022 (54,408)]  
EDSS 0 – 3:  
€9,184 (18,655) 
[CAN$ 7,151 (14,526)]  
EDSS 0 – 3:  
€25,496 (24,964) 
[CAN$ 19,853 (19,439)]  
EDSS 7 – 9:  
€31,438 (28,761) 
[CAN$ 24,480 (22,395)]  
EDSS 0 – 3:  
€39,601 (66,512) 
[CAN$ 30,836 (51,791) ] 
EDSS 0 – 3:  
€59,874 (43,961) 
[CAN$ 46,622 (34,231)] 
EDSS 7 – 9:   
€100,147 (80,018) 
[CAN$ 77,981 (62,307)]  
(using HUI) 
EDSS 1-2: 
utility 0.75 
EDSS 3-4: 
utility 0.65 
EDSS 5-6: 
utility 0.75 
 
- 2012  from 
[61] 
And [107] 
USA ( Euro, 
2011 
exchange 
rate ) 
Mean cost  
€8,547 – 48,010 (adjusted to 2011) 
[US$6144- 34,511] 
 
 
RRMS  €18,453 
[US$13,265] (2010–2011) 
 
Mean cost  
€2,638 – 27,451 
(adjusted to 2011)  
[US$1896- 19,733] 
RRMS:  
€125 – 7,374 
[US$90 (2012)–  
US$5,301 
(2010–2011)] 
SPMS: €527 – 1029 
[US$379–$740 (2012)] 
Mean cost  
€11,864 – 75,461 (adjusted 
to 2011)  
[US$ 8,528- 54,244] 
RRMS:  
€8,190 – 49,013 
[US$5,887 (2006)–
US$35,232 (2009)] 
PPMS /PMS:  
€32,873 
[US$23,630 (2006)] 
0.70 
 
0.22 2011 from 
Adelman et al 
2013 
USA 2012  
from [61] 
2006 from [7] 
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Appendix Table 5: Clinical uncertainties 
Clinical 
Uncertainties 
Description 
Clinical Benefits Uncertainties related to the real magnitude of the clinical benefit given by the drug appraised such as assuming the 
long-term effect of the medicines or the assumptions on retreatment rates or assumption on the discontinuation of 
treatment or on a return to a rate of progression equivalent to the natural history of the disease or on the choice of 
data. 
Study Design Uncertainties related to the statistical methodology or the conduct of the trial such as the loss of patients to follow-up, 
the inclusion of patient preferences during the trial conduct, the reliance of non-phase III trials results considered less 
robust, the uncertain nature of indirect comparisons, the assumptions around the trial design or randomisation the 
methodologies used for the subgroup analyses or pooling of trials, the unverifiable nature of the evidence, the risk of 
attrition bias, the primary endpoint that is not powered by the study, the appropriateness of the statistical methods 
used, or the use of historical control data. 
Population Uncertainties around the population generalizability of the trial results to local clinical practice, and the representation 
of the trial population to the indication being appraised, including issues around the baseline characteristics of 
patients.  
Sample Size Uncertainties stemming from the trial not being statistically powered due to small sample sizes. 
Safety Uncertainties relate to the safety profile of the drug studied such as if adverse events provoked by the drug are 
manageable considering the life extension and the health benefit gained or whether the withdrawals are possibly 
associated with the toxicity profile of the treatment, the higher risk of adverse events compared to the control arm, or 
the lack of comparative safety data.  
Comparator Uncertainties related to the suitability of the comparator(s) chosen in the analysis or the trial. 
HRQoL Uncertainties related to the absence of any quality of life data in the submission, absence of any improvement in 
quality of life, or the uncertain nature of its magnitude of improvement. 
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Clinical 
Uncertainties 
Description 
Cross-over 
Uncertainties related to the possibility to crossover after the first trial period leading to a possible bias in the real 
magnitude of clinical benefit of the drug.  
Resource Use 
Uncertainties related to the proper use of resource respect the country setting (e.g. hospitalisation days) from the 
treatment in the trials or the possibility of a change in the resource used by introducing the new drug (e.g effect of an 
oral administration of a particular drug on the health service) 
Duration of the 
trial 
Uncertainties related to the trial period considered too short to capture the drug’s long-term benefits or reflect clinical 
practice (e.g. interim data having been used as main evidence).  
Clinical Practice 
Uncertainties relate to the lack of optimal treatment sequence, or change in clinical practice in the last years or to the 
generalizability of the trial to the clinical practice of the country. 
Administration 
provision 
Uncertainties around the additional requirements from receiving a treatment (e.g. implications for service delivery, 
monitoring or need for hospital visits) or the uncertainties around the optimal dosage of treatment. 
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Appendix Table 6: Economic uncertainties 
Economic Uncertainties Description 
Clinical Uncertainties 
Clinical Benefit Uncertainties around the estimates of clinical benefit of both the treatment and comparator 
Clinical Practice 
Uncertainties on the place of the treatment in clinical practice, such as issues around a lack of agreement as to the 
best treatment pathway or that the use of therapies not commonly used in the clinical practice. 
Comparator  Uncertainties around the appropriateness of the comparator used in the model  
Conduct and design Uncertainties around the bias steaming from the conduct of the trial used to populate the economic model data 
Evidence and study design Uncertainties around the evidence used to populate the economic model data 
Economic Uncertainties 
Utility 
Uncertainties around the estimation given for the utility and disutility in the model such as such as whether it 
provides a good fit to the data, or whether the models enables to account for longer term data, or the inclusion of 
certain elements in the model. 
Methods  Uncertainties around the methods used in the economic model 
Effects Uncertainties around the estimation of the effects of the drug studied or the comparators 
Costs Uncertainties related to the inclusion or exclusion on certain costs.  
Resource Use Uncertainties related to the estimation of the resource used by the health sector.  
PAS 
Uncertainties related to the introduction of the Patients Access Scheme in the economic modelling leading to a 
underestimation of the ICER 
Modelling 
Uncertainties related to the proper application of statistical model and the modelling assumption made in the 
model  
Model Structure Uncertainties related to the structure of the model such as its length.  
Exploratory Multivariate analysis Uncertainties on how the effects of the treatment were extrapolated.  
Clinical Assumptions 
Uncertainties related to Structural assumptions used in the analysis, including those around the cost, effect, 
utilities or treatment pathway of the treatment.  
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Appendix Table 7: Time lapse between marketing authorization and completion of the HTA process 
Marketing 
authorisat
ion from 
EMA 
DRUG NAME NICE 
Lag 
(months) 
TLV 
Lag 
(months) 
HAS 
Lag 
(months) 
SMC 
Lag 
(months) 
IQWIG 
Lag 
(months) 
12/09/13 Alemtuzumab 01/05/14 8.00 20/02/14 5.00 N/A N/A 01/04/14 7.00 N/A N/A 
30/01/14 Dimethyl 
fumarate 
01/08/14 7.00 01/08/14 7.00 01/05/14 4.00 01/07/14 6.00 01/07/14 6.00 
17/03/11 Fingolimod 01/08/12 17.00 N/A N/A 01/07/11 4.00 01/11/14 44.00 01/01/12 10.00 
27/06/06 Natalizumab 01/08/07 14.00 01/12/06 6.00 01/01/07 7.00 01/05/14 95.00 N/A N/A 
26/08/13 Teriflunomide 01/01/14 5.00 01/05/14 9.00 01/06/14 10.00 01/02/14 6.00 01/12/13 4.00 
13/03/97 Interferon 
Beta- Avonex 
01/01/02 58.00 01/05/14 206.00 01/06/10 159.00 01/11/03 80.00 N/A N/A 
04/05/98 Interferon 
Beta- Rebif 
01/01/02 44.00 01/09/09 136.00 01/06/10 145.00 01/10/12 173.00 N/A N/A 
Median 
Lag 
  21.86  61.50  54.83  58.71  6.67 
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Appendix Table 8: Patient survey: Responses and socio-demographic data (Entire sample and country 
sub-groups) 
Characteristics , country 
specific case studies 
ALL USA UK FRANCE GERMANY ROMANIA 
Questionnaires completed 271 70 26 103 11 45 
Questionnaires used for 
analysis* 
246 70 25 97 10 44 
Age, mean (SD) 43.7 (6) 54.3 (11.2) 38.2 (12.5) 42.6 (10.7) 42.5 (10.2) 41  (9) 
Gender, Female (n, %) 205 (83%) 59 (85.5%) 18     (72%) 83 (85.6%) 10   (100%) 35     (80%) 
Marital status, % (n) 
Single 
Married or cohabiting 
Divorced  
Separated  
Widow 
 
42 (17.1%) 
165 (67.1%) 
26 (10.6%) 
9 (3.7%) 
3 (1.2%) 
 
8(11.4%) 
47(67.1%) 
12(17.1%) 
1(1.4%) 
2(2.9%) 
 
10(40%) 
12(48%) 
1(4%) 
2(16%) 
0% 
 
14(15%) 
67(70%) 
8(8%) 
6(6%) 
1(5%) 
 
2(20%) 
7(70%) 
1(10%) 
0% 
0% 
 
8(18.2%) 
32(72.7%) 
4(9.1%) 
0% 
0% 
Level of education, % (n) 
Primary 
Secondary School 
Certificate 
A levels 
University 
None 
 
6 (4.2%) 
29 (11.8%) 
73 (29.7%) 
112 (45.5%) 
21 (8.5%) 
 
4 (5.7%) 
8 (11.4%) 
3 (4.3%) 
54 (77%) 
1 (1.4%) 
 
1 (4%) 
3 (12%) 
7 (28%) 
14 (56%) 
0% 
 
0% 
14 (14.4%) 
35 (36.1%) 
41 (42.3%) 
2 (2.1%) 
 
1 (10%) 
4 (40%) 
3 (30%) 
2 (20%) 
0% 
 
0% 
0% 
25 (56.8%) 
1 (2.3%) 
18 (41%) 
Number of household 
members where you live, 
mean (sd) 
2.6 (0.2) 2.3 (1.1) 2.4(1.0) 2.6 (1.2) 2.7(1.1) 2.8(1.0) 
Age @ 1st symptoms , 
mean (sd) 
30.4   (3.1) 32.6   (12.4) 25.7  (9.7) 30.2  (9.9) 33.7 (9.3) 30  (8.9) 
Age @ diagnosis, mean 
(sd)                                                                                  
35.2   (4.4) 42.1   (12.3) 30.3  (6.5) 34.2 (10.4) 36.3  (8.4) 33.3 (7.5) 
Gap from symptoms to 
diagnosis (yrs) , mean (sd) 
4.8     (2.8) 9.5     (10.5) 4.6    (7.12) 3.9   (6.1) 2.6    (3.3) 3.3   (6.0) 
EARLY DISEASE 
MANAGEMENT**, n(%) 
 
LATE DISEASE 
MANAGEMENT , n(%) 
118   (48%) 
 
 
128 (52%) 
20    (28.6%) 
 
 
50   (71.4%) 
14  (56%) 
 
 
11  (44%) 
51 (52.6%) 
 
 
46 (47.4%) 
6   (24%) 
 
 
4   (16%) 
27   (61.4%) 
 
 
17   (38.6%) 
Type of MS, % (n) 
RRMS 
SPMS 
PPMS  
Unknown 
 
175 (66%) 
30 (11.3%) 
26  (9.8%) 
34 (12.8%) 
 
53  (73.6%) 
16  (22.2%) 
1    (1.4%) 
2    (2.8%) 
 
20   (74%) 
2     (7.4%) 
4    (14.8%) 
1     (3.7%) 
 
59  (53.2%) 
9    (8.1%) 
16  (14.4%) 
27  (24.3%) 
 
10 (100%) 
0% 
0% 
0% 
 
33  (73.3%) 
3    (6.7%) 
5    (11.1%) 
4    (8.9%) 
*16 questionnaires were received from countries not included in the study (1:Thailand, 1:Netherlands, 1:Hong 
Kong, 2:Poland, 2:Belgium, 3:Austria, 1:Czech Rep, 1:Spain, 1:Serbia, 2:Ireland, 1:Morocco) ** Early disease 
management:= initiation of DMT within 12 months of a single neurological attack (Clinically Isolated Syndrome - 
CIS) with MRI enhancing lesions [55, 76,77,51]. 
 
 
54 
 
Appendix Figure 1: Mean estimated prevalence and incidence (Global, Europe and each country case 
study) 
  
 
Note: Prevalence rates were kept consistent with figures reported by Multiple Sclerosis International 
Federation (MSIF)19, whereas incidence rates were consistent with results reported from EU17 and 
USA106 epidemiological studies. 
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Appendix Figure 2: HTAs of MS-DMTs: Types of clinical trials examined (Cumulative numbers by 
agencies) 
  
  
0 5 10 15 20 25 30
NICE…
SMC…
TLV…
HAS…
CADTH…
IQWIG…
Phase III
Phase II
Indirect comparison
Post-marketing surveillance
Extension
 
 
56 
 
 
Appendix Figure 3: HTAs of MS DMTs: Clinical endpoints used in clinical trials (Cumulative numbers by 
agencies) 
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Appendix Figure 4: HTAs of MS DMTs: Safety indicators (Cumulative numbers by agencies) 
 
 
Note: AEs = adverse events  
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Appendix Figure 5: HTAs of MS DMTs: Economic evidence uncertainties (Cumulative numbers by 
agencies) 
(Economic model) 
 
(Clinical evidence used in the economic model) 
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Appendix Figure 6: HTAs of MS DMTs: Clinical evidence uncertainties (Cumulative numbers by 
agencies) 
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List of abbreviations  
 
AAN  American Association of Neurology 
ABN  Association of British Neurologists  
AE  Adverse Event 
AIFA   Italian medicines agency (Italy, Agenzia Italiana del Farmaco)  
CADTH  Canadian Agency for Drugs and Technologies in Health (Canada)  
CNS  Central Nervous System  
CSF  Cerebro Spinal Fluid  
CDMS   Clinically Definite Multiple Sclerosis 
CIS  Clinical Isolated Syndrome 
CQG   Cost per QALY gained  
DALYs   Disability-Adjusted Life Years 
DMTs  Disease Modifying Treatments  
EDSS   Expanded Disability Status Scale 
EQ-5D-5L  EuroQol 5 dimensions 5 levels  
GA   Glatiramer Acetate 
HAS  Haute Autorité de Santé (France)  
HRQoL  Health Related Quality of Life 
HTA   Health Technology Assessment 
ICER   Incremental Cost Effectiveness Ratio 
IQWiG  Institute for quality and efficiency in healthcare (Germany, Institut für Qualität und 
Wirtschaftlichkeit im Gesundheitswesen) 
IFN   Interferon 
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MS   Multiple Sclerosis  
MSQLI   Multiple sclerosis Quality of Life Inventory  
MRI   Magnetic Resonance Imaging 
MSIF   Multiple Sclerosis International Federation 
NEDA   No Evidence of Disease Activity 
NICE   National Institute for Health and Care Excellence (England)  
PAS   Patient Access Scheme (England) 
PROMs   Patient Relevant Outcome Measures  
PRIMUS  Patient Reported outcome Indices for MUltiple Sclerosis  
PWMS  People With Multiple Sclerosis 
PPMS   Primary Progressive Multiple Sclerosis  
QALY   Quality Adjusted Life Year  
RES   Rapidly Evolving Severe relapsing remitting multiple sclerosis  
RRMS   Relapsing Remitting Multiple Sclerosis  
SMC   Scottish Medicines Consortium (Scotland) 
SPMS   Secondary Progressive Multiple Sclerosis  
SF-36   Short Form health survey 36-Item 
TLV Dental and Pharmaceutical Benefits Board (Sweden, Tandvårds-och 
läkemedelsförmånsverket)  
 
